Guidelines & Statements

Information will be available soon.

Id	Title of publication	DOI	Disease Area	Partner / Member	DZL Site	DZL Members with Authorship (* = Corresponding Author)	Reach	Year	Clinical Study Name (ohne Link)	Author	Work Type	Pubmed Link	Link Original Publication	Content
Id	Title of publication	DOI	Disease Area	Partner / Member	DZL Site	DZL Members with Authorship (* = Corresponding Author)	Reach	Year	Clinical Study Name (ohne Link)	Author	Work Type	Pubmed Link	Link Original Publication	Content
51.679	[S1 guideline: diagnosis and treatment of invasive pulmonary aspergillosis in critically ill/intensive care patients]	10.1007/s00063-025-01265-w	PALI	Thorax, UKHD	TLRC	C. Heußel	international	2025		D. Wichmann, M. Hoenigl, P. Koehler, C. Koenig, F. Lund, S. Mang, R. Strauß, M. Weigand, C. Hohmann, O. Kurzai, C. Heußel and M. Kochanek	Review	https://pubmed.ncbi.nlm.nih.gov/40116920/	https://link.springer.com/article/10.1007/s00063-025-01265-w	No abstract available.
51.664	[Management of adult bronchiectasis - Consensus-based Guidelines for the German Respiratory Society (DGP) e.?V. (AWMF registration number 020-030)]	10.1055/a-2311-9450	CFBE	Ghd, KUM, MHH, Thorax, UKHD, UKSH (Kiel), UMR	Assoziierter Partner, ARCN, BREATH, CPC-M, TLRC, UGMLC	F. C. Ringshausen, R. Diel, R. Koczulla, G. Rohde, H. Slevogt, T. Welte, J. Rademacher, P. Mertsch	international	2024		F. C. Ringshausen, I. Baumann, A. de Roux, S. Dettmer, R. Diel, M. Eichinger, S. Ewig, H. Flick, L. Hanitsch, T. Hillmann, R. Koczulla, M. Köhler, A. Koitschev, C. Kugler, T. Nüßlein, S. R. Ott, I. Pink, M. Pletz, G. Rohde, L. Sedlacek, H. Slevogt, U. Sommerwerck, S. Sutharsan, S. von Weihe, T. Welte, M. Wilken, J. Rademacher and P. Mertsch	Original	https://pubmed.ncbi.nlm.nih.gov/39515342/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2311-9450	Bronchiectasis is an etiologically heterogeneous, chronic, and often progressive respiratory disease characterized by irreversible bronchial dilation. It is frequently associated with significant symptom burden, multiple complications, and reduced quality of life. For several years, there has been a marked global increase in the prevalence of bronchiectasis, which is linked to a substantial economic burden on healthcare systems. This consensus-based guideline is the first German-language guideline addressing the management of bronchiectasis in adults. The guideline emphasizes the importance of thoracic imaging using CT for diagnosis and differentiation of bronchiectasis and highlights the significance of etiology in determining treatment approaches. Both non-drug and drug treatments are comprehensively covered. Non-pharmacological measures include smoking cessation, physiotherapy, physical training, rehabilitation, non-invasive ventilation, thoracic surgery, and lung transplantation. Pharmacological treatments focus on the long-term use of mucolytics, bronchodilators, anti-inflammatory medications, and antibiotics. Additionally, the guideline covers the challenges and strategies for managing upper airway involvement, comorbidities, and exacerbations, as well as socio-medical aspects and disability rights. The importance of patient education and self-management is also emphasized. Finally, the guideline addresses special life stages such as transition, family planning, pregnancy and parenthood, and palliative care. The aim is to ensure comprehensive, consensus-based, and patient-centered care, taking into account individual risks and needs.
51.665	[Pulmonary hypertension in adults with congenital heart disease in light of the 2022-ESC-PAH guidelines - Part II: Supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ transplantation, special management (shunt lesions, left ventricular disorders, univentricular hearts), interventions, intensive care, follow-up, future perspectives]	10.1055/a-2274-1025	PH	Thorax	TLRC	C. A. Eichstaedt, E. Grünig, S. Michel	national	2024		H. Kaemmerer, G. P. Diller, S. Achenbach, I. Dähnert, C. A. Eichstaedt, A. Eicken, A. Freiberger, S. Freilinger, R. Geiger, M. Gorenflo, E. Grünig, A. Hager, M. Huntgeburth, A. S. Kaemmerer-Suleiman, R. Kozlik-Feldmann, A. E. Lammers, N. Nagdyman, S. Michel, K. H. Schmidt, A. Uebing, F. von Scheidt and C. Apitz	Original	https://pubmed.ncbi.nlm.nih.gov/38788761/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2274-1025	The number of adults with congenital heart defects (CHD) is steadily rising and amounts to approximately 360,000 in Germany. CHD is often associated with pulmonary hypertension (PH), which may develop early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists or recurs in older age and is associated with significant morbidity and mortality.The revised European Society of Cardiology/European Respiratory Society 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of "adults with congenital heart disease" is addressed only relatively superficial in these guidelines. Therefore, in the present article, this topic is commented in detail from the perspective of congenital cardiology.
51.666	A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia	10.1183/23120541.00115-2023	General Lung and Other	MHH	BREATH	F. C. Ringshausen	international	2024		R. Kos, M. Goutaki, H. E. Kobbernagel, B. Rubbo, A. Shoemark, S. Aliberti, J. Altenburg, P. Anagnostopoulou, R. A. Athanazio, N. Beydon, S. D. Dell, N. Emiralioglu, T. W. Ferkol, M. R. Loebinger, N. Lorent, B. Maître, J. Marthin, L. C. Morgan, K. G. Nielsen, F. C. Ringshausen, M. Shteinberg, H. Tiddens, A. H. Maitland-Van der Zee, J. D. Chalmers, J. S. A. Lucas and E. G. Haarman	Original	https://pubmed.ncbi.nlm.nih.gov/38196895/	https://publications.ersnet.org/content/erjor/10/1/00115-2023	BACKGROUND: Consistent use of reliable and clinically appropriate outcome measures is a priority for clinical trials, with clear definitions to allow comparability. We aimed to develop a core outcome set (COS) for pulmonary disease interventions in primary ciliary dyskinesia (PCD). METHODS: A multidisciplinary international PCD expert panel was set up. A list of outcomes was created based on published literature. Using a modified three-round e-Delphi technique, the panel was asked to decide on relevant end-points related to pulmonary disease interventions and how they should be reported. First, inclusion of an outcome in the COS was determined. Second, the minimum information that should be reported per outcome. The third round finalised statements. Consensus was defined as ≥80% agreement among experts. RESULTS: During the first round, experts reached consensus on four out of 24 outcomes to be included in the COS. Five additional outcomes were discussed in subsequent rounds for their use in different subsettings. Consensus on standardised methods of reporting for the COS was reached. Spirometry, health-related quality-of-life scores, microbiology and exacerbations were included in the final COS. CONCLUSION: This expert consensus resulted in a COS for clinical trials on pulmonary health among people with PCD.
51.667	A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function	10.1002/ejhf.3236	PH	JLU, MHH	BREATH, UGMLC	S. S. Pullamsetti, T. Thum	international	2024		P. Ameri, V. Mercurio, P. Pollesello, M. S. Anker, J. Backs, A. Bayes-Genis, B. A. Borlaug, D. Burkhoff, S. Caravita, S. Y. Chan, F. de Man, G. Giannakoulas, A. González, M. Guazzi, P. M. Hassoun, A. R. Hemnes, C. Maack, B. Madden, V. Melenovsky, O. J. Müller, Z. Papp, S. S. Pullamsetti, P. P. Rainer, M. M. Redfield, S. Rich, G. G. Schiattarella, H. Skaara, K. Stellos, R. J. Tedford, T. Thum, J. L. Vachiery, P. van der Meer, S. Van Linthout, P. Pruszczyk, P. Seferovic, A. J. S. Coats, M. Metra, G. Rosano, S. Rosenkranz and C. G. Tocchetti	Review	https://pubmed.ncbi.nlm.nih.gov/38639017/	https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3236	Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
51.668	Assessment of Home-based Monitoring in Adults with Chronic Lung Disease. An Official American Thoracic Society Research Statement	10.1164/rccm.202410-2080ST	AA, CFBE, COPD, DPLD	Ghd	ARCN	H. Watz	international	2024		Y. H. Khor, V. Poberezhets, R. G. Buhr, J. D. Chalmers, H. Choi, V. S. Fan, M. George, A. E. Holland, H. Pinnock, C. J. Ryerson, R. Alder, K. I. Aronson, T. Barnes, R. Benzo, S. S. Birring, J. Boyd, B. Crossley, R. Flewett, M. Freedman, T. Gibson, L. Houchen-Wolloff, U. M. Krishnaswamy, J. Linnell, F. J. Martinez, C. C. Moor, H. Orr, A. A. Pappalardo, I. Saraiva, K. Wadell, H. Watz, M. S. Wijsenbeek and J. A. Krishnan	Original	https://pubmed.ncbi.nlm.nih.gov/39585746/	https://www.atsjournals.org/doi/10.1164/rccm.202410-2080ST	Background: There is increasing interest in the use of home-based monitoring in people with chronic lung diseases to improve access to care, support patient self-management, and facilitate the collection of information for clinical care and research. However, integration of home-based monitoring into clinical and research settings requires careful consideration of test performance and other attributes. There is no published guidance from professional respiratory societies to advance the science of home-based monitoring for chronic lung disease. Methods: An international multidisciplinary panel of 32 clinicians, researchers, patients, and caregivers developed a multidimensional framework for the evaluation of home-based monitoring in chronic lung disease developed through consensus using a modified Delphi survey. We also present an example of how the framework could be used to evaluate home-based monitoring using spirometry and pulse oximetry in adults with asthma, bronchiectasis/cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). Results: The PANACEA framework includes seven domains (test Performance, disease mANAgement, Cost, patient Experience, clinician Experience, researcher Experience, and Access) to assess the degree to which home-based monitoring assessments meet the conditions for clinical and research use in chronic lung disease. Knowledge gaps and recommendations for future research of home spirometry and pulse oximetry in asthma, bronchiectasis/CF, COPD, and ILD were identified. Conclusion: The development of the PANACEA framework allows standardized evaluation of home-based monitoring in chronic lung diseases to support clinical application and future research.
51.669	AWMF mold guideline "Medical clinical diagnostics for indoor mold exposure" - Update 2023 AWMF Register No. 161/001	10.5414/alx02444e	AA	JLU, KUM	CPC-M, UGMLC	D. Nowak	national	2024		J. Hurraß, B. Heinzow, S. Walser-Reichenbach, U. Aurbach, S. Becker, R. Bellmann, K. C. Bergmann, O. A. Cornely, S. Engelhart, G. Fischer, T. Gabrio, C. E. W. Herr, M. Joest, C. Karagiannidis, L. Klimek, M. Köberle, A. Kolk, H. Lichtnecker, T. Lob-Corzilius, N. Mülleneisen, D. Nowak, U. Rabe, M. Raulf, J. Steinmann, J. O. Steiß, J. Stemler, U. Umpfenbach, K. Valtanen, B. Werchan, B. Willinger and G. A. Wiesmüller	Original	https://pubmed.ncbi.nlm.nih.gov/38756207/	https://www.dustri.com/article_response_page.html?artId=191166&doi=10.5414/ALX02444E&L=0	None.
51.670	ERS statement on transition of care in childhood interstitial lung diseases	10.1183/13993003.02160-2023	DPLD	KUM	CPC-M	M. Griese	international	2024		P. Pohunek, E. Manali, S. Vijverberg, J. Carlens, F. Chua, R. Epaud, C. Gilbert, M. Griese, B. Karadag, E. Kerem, V. Koucký, N. Nathan, S. Papiris, S. Terheggen-Lagro, L. Plch, A. T. Vernetta and A. Bush	Original	https://pubmed.ncbi.nlm.nih.gov/38843911/	https://publications.ersnet.org/content/erj/64/2/2302160	Interstitial lung diseases (ILD) are a heterogeneous group of rare diffuse diseases affecting the lung parenchyma in children and adults. Childhood interstitial lung diseases (chILD) are often diagnosed at very young age, affect the developing lung, and can have different presentations and prognosis compared to adult forms of these diseases. Also, chILD in many cases may apparently remit, and have a better response to therapy and better prognosis than adult ILD. Many affected children will reach adulthood with minimal activity or clinical remission of the disease. They need continuing care and follow-up from childhood to adulthood if the disease persists and progresses over time but also if they are asymptomatic and in full remission. Therefore, for every chILD patient an active transition process from paediatric to adult care should be guaranteed. This ERS statement provides a review of the literature and current practice concerning transition of care in chILD. It draws on work in existing transition care programs in other chronic respiratory diseases, disease-overarching transition of care programs, evidence on the impact of these programs on clinical outcomes, current evidence regarding long-term remission of chILD as well as the lack of harmonisation between the current adult ILD and chILD classifications impacting on transition of care. While the transition system is well established in several chronic diseases, such as cystic fibrosis or diabetes mellitus, we could not find sufficient published evidence on transition systems in chILD. This statement summarises current knowledge but cannot yet provide evidence-based recommendations for clinical practice.
51.671	European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis	10.1183/13993003.00725-2024	DPLD	KUM	CPC-M	M. Griese	international	2024		C. McCarthy, F. Bonella, M. O'Callaghan, C. Dupin, T. Alfaro, M. Fally, R. Borie, I. Campo, V. Cottin, A. Fabre, M. Griese, A. Hadchouel, S. Jouneau, M. Kokosi, E. Manali, H. Prosch, B. Trapnell, M. Veltkamp, T. Wang, I. Toews, A. Mathioudakis and E. Bendstrup	Original	https://pubmed.ncbi.nlm.nih.gov/39147411/	https://publications.ersnet.org/content/erj/64/5/2400725	BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several distinct diseases leading to progressive dyspnoea, hypoxemia, risk of respiratory failure and early death due to accumulation of proteinaceous material in the lungs. Diagnostic strategies may include computed tomography (CT) of the lungs, bronchoalveolar lavage, evaluation of antibodies against granulocyte macrophage colony stimulating factor (GM-CSF), genetic testing, and, eventually, lung biopsy. The management options are focused at removing the proteinaceous material by whole lung lavage (WLL), augmentation therapy with GM-CSF, rituximab, plasmapheresis, and lung transplantation. The presented diagnostic and management guideline aim to provide guidance to physicians managing patients with PAP. METHODS: A European Respiratory Society Task Force committee composed of clinicians, methodologists, and patients with experience in PAP developed recommendations in accordance with the ERS Handbook for Clinical Practice Guidelines and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. This included a systematic review of the literature and application of the GRADE approach to assess the certainty of the evidence and strength of recommendations. The committee formulated five PICO (Patients, Intervention, Comparison, Outcomes) questions, and two narrative questions to develop specific evidence-based recommendations. RESULTS: The Task Force committee developed recommendations for five PICOs. These included management of PAP with WLL, GM-CSF augmentation therapy, rituximab, plasmapheresis, and lung transplantation. Also, the committee made recommendations regarding the use of GM-CSF antibody testing, diagnostic bronchoalveolar lavage (BAL) and biopsy based on narrative questions.In addition to the recommendations, the committee provided information on the hierarchy of diagnostic interventions and therapy. CONCLUSIONS: The diagnosis of PAP is based on CT and BAL cytology or lung histology, whereas diagnosis of specific PAP-causing diseases requires GM-CSF antibody testing or genetic analysis. There are several therapies including WLL and augmentation therapy with GM-CSF available to treat PAP, but supporting evidence is still limited.
51.673	Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007	10.1007/s15010-024-02358-y	PALI	MHH, Thorax	BREATH, TLRC	J. Rademacher, C. P. Heußel, G. Rohde, T. Welte	national	2024		J. Rademacher, S. Ewig, B. Grabein, I. Nachtigall, M. Abele-Horn, M. Deja, M. Gaßner, S. Gatermann, C. Geffers, H. Gerlach, S. Hagel, C. P. Heußel, S. Kluge, M. Kolditz, E. Kramme, H. Kühl, M. Panning, P. M. Rath, G. Rohde, B. Schaaf, H. J. F. Salzer, D. Schreiter, H. Schweisfurth, S. Unverzagt, M. A. Weigand, T. Welte and M. W. Pletz	Original	https://pubmed.ncbi.nlm.nih.gov/39115698/	https://link.springer.com/article/10.1007/s15010-024-02358-y	PURPOSE: This executive summary of a German national guideline aims to provide the most relevant evidence-based recommendations on the diagnosis and treatment of nosocomial pneumonia. METHODS: The guideline made use of a systematic assessment and decision process using evidence to decision framework (GRADE). Recommendations were consented by an interdisciplinary panel. Evidence analysis and interpretation was supported by the German innovation fund providing extensive literature searches and (meta-) analyses by an independent methodologist. For this executive summary, selected key recommendations are presented including the quality of evidence and rationale for the level of recommendation. RESULTS: The original guideline contains 26 recommendations for the diagnosis and treatment of adults with nosocomial pneumonia, thirteen of which are based on systematic review and/or meta-analysis, while the other 13 represent consensus expert opinion. For this key summary, we present 11 most relevant for everyday clinical practice key recommendations with evidence overview and rationale, of which two are expert consensus and 9 evidence-based (4 strong, 5 weak and 2 open recommendations). For the management of nosocomial pneumonia patients should be divided in those with and without risk factors for multidrug-resistant pathogens and/or Pseudomonas aeruginosa. Bacterial multiplex-polymerase chain reaction (PCR) should not be used routinely. Bronchoscopic diagnosis is not considered superior to´non-bronchoscopic sampling in terms of main outcomes. Only patients with septic shock and the presence of an additional risk factor for multidrug-resistant pathogens (MDRP) should receive empiric combination therapy. In clinically stabilized patients, antibiotic therapy should be de-escalated and focused. In critically ill patients, prolonged application of suitable beta-lactam antibiotics should be preferred. Therapy duration is suggested for 7-8 days. Procalcitonin (PCT) based algorithm might be used to shorten the duration of antibiotic treatment. Patients on the intensive care unit (ICU) are at risk for invasive pulmonary aspergillosis (IPA). Diagnostics for Aspergillus should be performed with an antigen test from bronchial lavage fluid. CONCLUSION: The current guideline focuses on German epidemiology and standards of care. It should be a guide for the current treatment and management of nosocomial pneumonia in Germany.
51.674	Occupational lung cancer screening: A Collegium Ramazzini statement	10.1002/ajim.23572	LC	KUM	CPC-M	D. Nowak	international	2024		S. Markowitz, K. Ringen, J. M. Dement, K. Straif, L. Christine Oliver, E. Algranti, D. Nowak, R. Ehrlich, M. A. McDiarmid and A. Miller	Original	https://pubmed.ncbi.nlm.nih.gov/38440821/	https://onlinelibrary.wiley.com/doi/10.1002/ajim.23572	No abstract available.
51.675	Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement	10.1164/rccm.202406-1168ST	LC	JLU, MPI-BN	UGMLC	R. Savai	international	2024		S. J. Moghaddam, R. Savai, R. Salehi-Rad, S. Sengupta, M. N. Kammer, P. Massion, J. E. Beane, E. J. Ostrin, C. Priolo, M. A. Tennis, L. P. Stabile, A. K. Bauer, C. R. Sears, E. Szabo, M. P. Rivera, C. A. Powell, H. Kadara, B. J. Jenkins, S. M. Dubinett, A. M. Houghton, C. F. Kim and R. L. Keith	Original	https://pubmed.ncbi.nlm.nih.gov/39115548/	https://www.atsjournals.org/doi/10.1164/rccm.202406-1168ST	RATIONALE: Despite significant advances in precision treatments and immunotherapy, lung cancer is the most common cause of cancer death worldwide. To reduce incidence and improve survival rates, a deeper understanding of lung premalignancy and the multistep process of tumorigenesis is essential, allowing for timely and effective intervention before cancer development. OBJECTIVES: To summarize existing information, identify knowledge gaps, formulate research questions, prioritize potential research topics, and propose strategies for future investigations into the premalignant progression in the lung. METHODS: An international multidisciplinary team of basic, translational, and clinical scientists reviewed available data to develop and refine research questions pertaining to the transformation of premalignant lung lesions to advanced lung cancer. RESULTS: This research statement identifies significant gaps in knowledge and proposes potential research questions aimed at expanding our understanding of the mechanisms underlying the progression of premalignant lung lesions to lung cancer in an effort to explore potential innovative modalities to intercept lung cancer at its nascent stages. CONCLUSIONS: The identified gaps in knowledge about the biological mechanisms of premalignant progression in the lung, along with ongoing challenges in screening, detection, and early intervention, highlight the critical need to prioritize research in this domain. Such focused investigations are essential to devise effective preventive strategies that may ultimately decrease lung cancer incidence and improve patient outcomes.
51.676	Pulmonary hypertension in adults with congenital heart defects (ACHDs)-in light of the 2022 ESC PAH guidelines-part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects	10.21037/cdt-24-148	PH	KUM, Thorax, UKHD, UKSH (Kiel)	Assoziierter Partner, CPC-M, TLRC	C. A. Eichstaedt, E. Grünig, S. Michel	national	2024		H. Kaemmerer, G. P. Diller, I. Dähnert, S. Achenbach, C. A. Eichstaedt, A. Eicken, A. Freiberger, S. Freilinger, R. Geiger, M. Gorenflo, E. Grünig, A. Hager, M. Huntgeburth, A. S. Kaemmerer-Suleiman, R. Kozlik-Feldmann, A. E. Lammers, N. Nagdyman, S. Michel, K. H. Schmidt, M. Suleiman, A. Uebing, F. von Scheidt, U. Herberg and C. Apitz	Review	https://pubmed.ncbi.nlm.nih.gov/39513141/	https://cdt.amegroups.org/article/view/130029/html	The number of adults with congenital heart defects (ACHDs) is steadily increasing and is about 360,000 in Germany. Congenital heart defect (CHD) is often associated with pulmonary hypertension (PH), which sometimes develops early in untreated CHD. Despite timely treatment of CHD, PH not infrequently persists, redevelops in older age, and is associated with significant morbidity and lethality. The revised European Society of Cardiology (ESC)/European Respiratory Society (ERS) 2022 guidelines for the diagnosis and treatment of PH represent a significant contribution to the optimized care of those affected. However, the topic of "adults with congenital heart defects" is treated only relatively superficially in this context. In the present article, part I, therefore, this topic is commented on in detail from the perspective of congenital cardiology with a special focus on definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up and gender aspects of PH in ACHDs. This paper consists of two parts. Part II will provide comments on the topics of supportive therapy, special situations like pregnancy, contraception, and non-cardiac surgery, targeted pharmacotherapy, organ transplantation, special management like shunt lesion, left ventricular disease, and univentricular hearts, interventions, intensive care, ACHDs follow-up and future perspective on PH in ACHDs. By examining these aspects in detail, this article aims to fill the gaps in the existing guidelines and provide a more thorough understanding from the perspective of congenital cardiology.
51.677	Radiomics workflow definition & challenges - German priority program 2177 consensus statement on clinically applied radiomics	10.1186/s13244-024-01704-w	PLI	DKFZ, RKU, UKHD	TLRC	J. Bohn	international	2024		R. Floca, J. Bohn, C. Haux, B. Wiestler, F. G. Zöllner, A. Reinke, J. Weiß, M. Nolden, S. Albert, T. Persigehl, T. Norajitra, B. Baeßler, M. Dewey, R. Braren, M. Büchert, E. M. Fallenberg, N. Galldiks, A. Gerken, M. Götz, H. K. Hahn, J. Haubold, T. Haueise, N. Große Hokamp, M. Ingrisch, A. I. Iuga, M. Janoschke, M. Jung, L. S. Kiefer, P. Lohmann, J. Machann, J. H. Moltz, J. Nattenmüller, T. Nonnenmacher, B. Oerther, A. E. Othman, F. Peisen, F. Schick, L. Umutlu, B. D. Wichtmann, W. Zhao, S. Caspers, H. P. Schlemmer, C. L. Schlett, K. Maier-Hein and F. Bamberg	Original	https://pubmed.ncbi.nlm.nih.gov/38825600/	https://insightsimaging.springeropen.com/articles/10.1186/s13244-024-01704-w	OBJECTIVES: Achieving a consensus on a definition for different aspects of radiomics workflows to support their translation into clinical usage. Furthermore, to assess the perspective of experts on important challenges for a successful clinical workflow implementation. MATERIALS AND METHODS: The consensus was achieved by a multi-stage process. Stage 1 comprised a definition screening, a retrospective analysis with semantic mapping of terms found in 22 workflow definitions, and the compilation of an initial baseline definition. Stages 2 and 3 consisted of a Delphi process with over 45 experts hailing from sites participating in the German Research Foundation (DFG) Priority Program 2177. Stage 2 aimed to achieve a broad consensus for a definition proposal, while stage 3 identified the importance of translational challenges. RESULTS: Workflow definitions from 22 publications (published 2012-2020) were analyzed. Sixty-nine definition terms were extracted, mapped, and semantic ambiguities (e.g., homonymous and synonymous terms) were identified and resolved. The consensus definition was developed via a Delphi process. The final definition comprising seven phases and 37 aspects reached a high overall consensus (> 89% of experts "agree" or "strongly agree"). Two aspects reached no strong consensus. In addition, the Delphi process identified and characterized from the participating experts' perspective the ten most important challenges in radiomics workflows. CONCLUSION: To overcome semantic inconsistencies between existing definitions and offer a well-defined, broad, referenceable terminology, a consensus workflow definition for radiomics-based setups and a terms mapping to existing literature was compiled. Moreover, the most relevant challenges towards clinical application were characterized. CRITICAL RELEVANCE STATEMENT: Lack of standardization represents one major obstacle to successful clinical translation of radiomics. Here, we report a consensus workflow definition on different aspects of radiomics studies and highlight important challenges to advance the clinical adoption of radiomics. KEY POINTS: Published radiomics workflow terminologies are inconsistent, hindering standardization and translation. A consensus radiomics workflow definition proposal with high agreement was developed. Publicly available result resources for further exploitation by the scientific community.
51.678	World Association for Bronchology and Interventional Pulmonology (WABIP) guidelines on airway stenting for malignant central airway obstruction	10.1111/resp.14764	COPD	Thorax	TLRC	F. Herth	international	2024		U. Chaddha, A. Agrawal, J. Kurman, R. Ortiz-Comino, H. Dutau, L. Freitag, R. Trisolini, C. Dooms, L. Zuccatosta, S. Gasparini, F. Herth, H. Saka, P. Lee, D. Fielding, M. Oki, A. Rosell and S. Murgu	Original	https://pubmed.ncbi.nlm.nih.gov/38812262/	https://onlinelibrary.wiley.com/doi/10.1111/resp.14764	Malignant Central Airway Obstruction (MCAO) encompasses significant and symptomatic narrowing of the central airways that can occur due to primary lung cancer or metastatic disease. Therapeutic bronchoscopy is associated with high technical success and symptomatic relief and includes a wide range of airway interventions including airway stents. Published literature suggests that stenting practices vary significantly across the world primarily due to lack of guidance. This document aims to address this knowledge gap by addressing relevant questions related to airway stenting in MCAO. An international group of 17 experts from 17 institutions across 11 countries with experience in using airway stenting for MCAO was convened as part of this guideline statement through the World Association for Bronchology and Interventional Pulmonology (WABIP). We performed a literature and internet search for reports addressing six clinically relevant questions. This guideline statement, consisting of recommendations addressing these six PICO questions, was formulated by a systematic and rigorous process involving the evaluation of published evidence, augmented with expert experience when necessary. Panel members participated in the development of the final recommendations using the modified Delphi technique.
51.672	ISHLT consensus statement on the perioperative use of ECLS in lung transplantation: Part II: Intraoperative considerations	10.1016/j.healun.2024.08.027	ROR	KUM	CPC-M	J. Behr	international	2024		A. K. Martin, O. Mercier, A. V. Fritz, T. A. Gelzinis, K. Hoetzenecker, S. Lindstedt, N. Marczin, B. J. Wilkey, M. Schecter, H. Lyster, M. Sanchez, J. Walsh, O. Morrissey, B. Levvey, C. Landry, S. Saatee, S. Kotecha, J. Behr, J. Kukreja, G. Dellgren, J. Fessler, B. Bottiger, K. Wille, K. Dave, B. S. Nasir, D. Gomez-De-Antonio, M. Cypel and A. K. Reed	Original	https://pubmed.ncbi.nlm.nih.gov/39453286/	https://www.jhltonline.org/article/S1053-2498(24)01830-8/fulltext	The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 39 recommendations regarding intraoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the planning, implementation, management, and monitoring of ECLS throughout the entire intraoperative period.
51.653	ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer	10.1093/ejcts/ezad302	LC, PLI	UKH	TLRC	J. Biederer, H. U. Kauczor	international	2023		E. L. O'Dowd, I. Tietzova, E. Bartlett, A. Devaraj, J. Biederer, M. Brambilla, A. Brunelli, J. Chorostowska, H. Decaluwe, D. Deruysscher, W. De Wever, M. Donoghue, A. Fabre, M. Gaga, W. van Geffen, G. Hardavella, H. U. Kauczor, A. Kerpel-Fronius, J. van Meerbeeck, B. Nagavci, U. Nestle, N. Novoa, H. Prosch, M. Prokop, P. M. Putora, J. Rawlinson, M. P. Revel, A. Snoeckx, G. Veronesi, R. Vliegenthart, S. Weckbach, T. G. Blum and D. R. Baldwin	Review	https://pubmed.ncbi.nlm.nih.gov/37804174/	https://academic.oup.com/ejcts/article/64/4/ezad302/7295842?login=true	BACKGROUND: Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that will ensure clinical and cost effectiveness. This European Respiratory Society (ERS) task force was formed to provide an expert consensus for the management of incidental findings which can be adapted and followed during implementation. METHODS: A multi-European society collaborative group was convened. 23 topics were identified, primarily from an ERS statement on lung cancer screening, and a systematic review of the literature was conducted according to ERS standards. Initial review of abstracts was completed and full text was provided to members of the group for each topic. Sections were edited and the final document approved by all members and the ERS Science Council. RESULTS: Nine topics considered most important and frequent were reviewed as standalone topics (interstitial lung abnormalities, emphysema, bronchiectasis, consolidation, coronary calcification, aortic valve disease, mediastinal mass, mediastinal lymph nodes and thyroid abnormalities). Other topics considered of lower importance or infrequent were grouped into generic categories, suitable for general statements. CONCLUSIONS: This European collaborative group has produced an incidental findings statement that can be followed during lung cancer screening. It will ensure that an evidence-based approach is used for reporting and managing incidental findings, which will mean that harms are minimised and any programme is as cost-effective as possible.
51.652	ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer	10.1183/13993003.00533-2023	LC, PLI	UKH	TLRC	J. Biederer, H. U. Kauczor	international	2023		E. L. O'Dowd, I. Tietzova, E. Bartlett, A. Devaraj, J. Biederer, M. Brambilla, A. Brunelli, J. Chorostowska, H. Decaluwe, D. Deruysscher, W. De Wever, M. Donoghue, A. Fabre, M. Gaga, W. van Geffen, G. Hardavella, H. U. Kauczor, A. Kerpel-Fronius, J. van Meerbeeck, B. Nagavci, U. Nestle, N. Novoa, H. Prosch, M. Prokop, P. M. Putora, J. Rawlinson, M. P. Revel, A. Snoeckx, G. Veronesi, R. Vliegenthart, S. Weckbach, T. G. Blum and D. R. Baldwin	Original	https://pubmed.ncbi.nlm.nih.gov/37802631/	https://publications.ersnet.org/content/erj/62/4/2300533	BACKGROUND: Screening for lung cancer with low radiation dose computed tomography has a strong evidence base, is being introduced in several European countries and is recommended as a new targeted cancer screening programme. The imperative now is to ensure that implementation follows an evidence-based process that will ensure clinical and cost effectiveness. This European Respiratory Society (ERS) task force was formed to provide an expert consensus for the management of incidental findings which can be adapted and followed during implementation. METHODS: A multi-European society collaborative group was convened. 23 topics were identified, primarily from an ERS statement on lung cancer screening, and a systematic review of the literature was conducted according to ERS standards. Initial review of abstracts was completed and full text was provided to members of the group for each topic. Sections were edited and the final document approved by all members and the ERS Science Council. RESULTS: Nine topics considered most important and frequent were reviewed as standalone topics (interstitial lung abnormalities, emphysema, bronchiectasis, consolidation, coronary calcification, aortic valve disease, mediastinal mass, mediastinal lymph nodes and thyroid abnormalities). Other topics considered of lower importance or infrequent were grouped into generic categories, suitable for general statements. CONCLUSIONS: This European collaborative group has produced an incidental findings statement that can be followed during lung cancer screening. It will ensure that an evidence-based approach is used for reporting and managing incidental findings, which will mean that harms are minimised and any programme is as cost-effective as possible.
51.651	ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	10.1007/s00134-023-07033-8	ALI	MHH	BREATH	T. Welte	international	2023		I. Martin-Loeches, A. Torres, B. Nagavci, S. Aliberti, M. Antonelli, M. Bassetti, L. D. Bos, J. D. Chalmers, L. Derde, J. de Waele, J. Garnacho-Montero, M. Kollef, C. M. Luna, R. Menendez, M. S. Niederman, D. Ponomarev, M. I. Restrepo, D. Rigau, M. J. Schultz, E. Weiss, T. Welte and R. Wunderink	Original	https://pubmed.ncbi.nlm.nih.gov/37012484/	https://link.springer.com/article/10.1007/s00134-023-07033-8	PURPOSE: Severe community-acquired pneumonia (sCAP) is associated with high morbidity and mortality, and whilst European and non-European guidelines are available for community-acquired pneumonia, there are no specific guidelines for sCAP. METHODS: The European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Latin American Thoracic Association (ALAT) launched a task force to develop the first international guidelines for sCAP. The panel comprised a total of 18 European and four non-European experts, as well as two methodologists. Eight clinical questions for sCAP diagnosis and treatment were chosen to be addressed. Systematic literature searches were performed in several databases. Meta-analyses were performed for evidence synthesis, whenever possible. The quality of evidence was assessed with GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Evidence to Decision frameworks were used to decide on the direction and strength of recommendations. RESULTS: Recommendations issued were related to diagnosis, antibiotics, organ support, biomarkers and co-adjuvant therapy. After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention and implications to health equity, recommendations were made for or against specific treatment interventions. CONCLUSIONS: In these international guidelines, ERS, ESICM, ESCMID, and ALAT provide evidence-based clinical practice recommendations for diagnosis, empirical treatment, and antibiotic therapy for sCAP, following the GRADE approach. Furthermore, current knowledge gaps have been highlighted and recommendations for future research have been made.
51.650	ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	10.1183/13993003.00735-2022	ALI	MHH	BREATH	T. Welte	international	2023		I. Martin-Loeches, A. Torres, B. Nagavci, S. Aliberti, M. Antonelli, M. Bassetti, L. Bos, J. D. Chalmers, L. Derde, J. de Waele, J. Garnacho-Montero, M. Kollef, C. Luna, R. Menendez, M. Niederman, D. Ponomarev, M. Restrepo, D. Rigau, M. J. Schultz, E. Weiss, T. Welte and R. Wunderink	Original	https://pubmed.ncbi.nlm.nih.gov/37012080/	https://publications.ersnet.org/content/erj/61/4/2200735	BACKGROUND: Severe community-acquired pneumonia (sCAP) is associated with high morbidity and mortality, and while European and non-European guidelines are available for community-acquired pneumonia, there are no specific guidelines for sCAP. MATERIALS AND METHODOLOGY: The European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Latin American Thoracic Association (ALAT) launched a task force to develop the first international guidelines for sCAP. The panel comprised a total of 18 European and four non-European experts, as well as two methodologists. Eight clinical questions for sCAP diagnosis and treatment were chosen to be addressed. Systematic literature searches were performed in several databases. Meta-analyses were performed for evidence synthesis, whenever possible. The quality of evidence was assessed with GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Evidence to Decision frameworks were used to decide on the direction and strength of recommendations. RESULTS: Recommendations issued were related to diagnosis, antibiotics, organ support, biomarkers and co-adjuvant therapy. After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention and implications to health equity, recommendations were made for or against specific treatment interventions. CONCLUSIONS: In these international guidelines, ERS, ESICM, ESCMID and ALAT provide evidence-based clinical practice recommendations for diagnosis, empirical treatment and antibiotic therapy for sCAP, following the GRADE approach. Furthermore, current knowledge gaps have been highlighted and recommendations for future research have been made.
51.649	Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	10.1007/s00134-023-07082-z	ALI	MHH	BREATH	T. Welte	international	2023		I. Martin-Loeches, A. Torres, B. Nagavci, S. Aliberti, M. Antonelli, M. Bassetti, L. D. Bos, J. D. Chalmers, L. Derde, J. De Waele, J. Garnacho-Montero, M. Kollef, C. M. Luna, R. Menendez, M. S. Niederman, D. Ponomarev, M. I. Restrepo, D. Rigau, M. J. Schultz, E. Weiss, T. Welte and R. Wunderink	Other	https://pubmed.ncbi.nlm.nih.gov/37195462/	https://link.springer.com/article/10.1007/s00134-023-07082-z	No abstract available.
51.648	[Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM)]	10.1007/s00106-023-01273-2	AA	KUM	CPC-M	K. Milger-Kneidinger	national	2023		O. Pfaar, A. G. Beule, M. Laudien, B. A. Stuck and C. erweiterte Leitliniengruppe 'Biologika bei	Review	https://www.ncbi.nlm.nih.gov/pubmed/36941387	https://link.springer.com/article/10.1007/s00106-023-01273-2	Monoclonal antibodies (so-called biologics) can be prescribed for chronic rhinosinusitis with nasal polyps (CRSwNP) within the scope of their market authorization. However, their prescription is limited to severe CRSwNP without disease control, whereby certain requirements must be met. Dupilumab, omalizumab, and mepolizumab have currently gained market authorization, with adequate evidence for their efficacy and safety available in the literature. It can be assumed that other biologics will be approved for this indication in the future. The severity of disease and the efficacy of treatment should be assessed objectively and subjectively before treatment initiation and after an appropriate duration, respectively. The documentation sheet proposed in this guideline chapter can be used for the assessments. In the presence of relative contraindications, a treatment should only be initiated after differentiated consideration by an experienced physician in the sense of a case-by-case decision. In summary, this guideline chapter aims to contribute to high-quality care of adult patients with these therapies in view of the increasing evidence for treatment with these substances and the increasing number of market authorizations of different biologics.
51.647	[The new European Guidelines for Pulmonary Hypertension with Updated Commentary of the PH-DACH Conference - A position paper of the German Society for Pneumology and Respiratory Medicine (DGP)]	10.1055/a-2146-7472	PH	JLU, KUM, Thorax	CPC-M, TLRC, UGMLC	E. Grünig, J. Behr, Milger-Kneidinger, W. M. Kuebler, K. Tello	national	2023		E. Grünig, N. Benjamin, J. Behr, D. Skowasch, K. Milger-Kneidinger, M. Halank, W. M. Kuebler, G. Kovacs, M. Lichtblau, S. Guth, C. Apitz, H. Kaemmerer, K. Tello and S. Ulrich	Original	https://pubmed.ncbi.nlm.nih.gov/37963474/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2146-7472	No abstract available.
51.646	[Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]	10.1055/a-2178-2846	LC, PLI	JLU, MHH, UKH	BREATH, TLRC, UGMLC	J. Vogel-Claussen, T. G. Blum, S. Andreas, T. T. Bauer, J. Barkhausen, V. Harth, H. U. Kauczor, W. Pankow, K. Welcker, R. Kaaks and H. Hoffmann	national	2023		J. Vogel-Claussen, S. Andreas, H. U. Kauczor, R. Kaaks	Original	https://pubmed.ncbi.nlm.nih.gov/37816377/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2178-2846	The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on the early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present key points for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process. CITATION FORMAT: · Vogel-Claussen J, Blum TG, Andreas S et al. Position paper on the implementation of a nationally organized program in Germany for the early detection of lung cancer in high-risk populations using low-dose CT screening including the management of screening findings requiring further workup. Fortschr Röntgenstr 2023; DOI 10.1055/a-2178-2846.
51.645	[Statement Paper on the Implementation of a National Organized Program in Germany for the Early Detection of Lung Cancer in Risk Populations Using Low-dose CT Screening Including Management of Screening Findings]	10.1055/a-2178-5907	LC	DKFZ, JLU, MHH	BREATH, TLRC, UGMLC	R. Kaaks, S. Andreas, H. U. Kauczor, J. Vogel-Claussen	national	2023		H. Hoffmann, R. Kaaks, S. Andreas, T. T. Bauer, J. Barkhausen, V. Harth, H. U. Kauczor, W. Pankow, K. Welcker, J. Vogel-Claussen and T. G. Blum	Original	https://pubmed.ncbi.nlm.nih.gov/37816386/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2178-5907	The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process.
51.644	[Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]	10.1055/a-2175-4580	LC	DKFZ, JLU, MHH, UKH	BREATH, TLRC, UGMLC	J. Vogel-Claussen, S. Andreas, H. U. Kauczor, R. Kaaks	national	2023		T. G. Blum, J. Vogel-Claussen, S. Andreas, T. T. Bauer, J. Barkhausen, V. Harth, H. U. Kauczor, W. Pankow, K. Welcker, R. Kaaks and H. Hoffmann	Original	https://pubmed.ncbi.nlm.nih.gov/37816379/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2175-4580	The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process.
51.661	[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]	10.1055/a-2182-1907	CFBE	KUM, MHH, RKU	BREATH, CPC-M, TLRC	M. O. Wielpütz, J. Ley-Zaporozhan, F. C. Ringshausen, O. Sommerburg	national	2024		C. Schwarz, J. Bend, H. Hebestreit, M. Hogardt, C. Hügel, S. Illing, J. G. Mainz, E. Rietschel, S. Schmidt, B. Schulte-Hubbert, H. Sitter, M. O. Wielpütz, J. Hammermann, I. Baumann, F. Brunsmann, D. Dieninghoff, E. Eber, H. Ellemunter, P. Eschenhagen, C. Evers, S. Gruber, A. Koitschev, J. Ley-Zaporozhan, U. Düesberg, H. J. Mentzel, T. Nüßlein, F. C. Ringshausen, L. Sedlacek, C. Smaczny, O. Sommerburg, S. Sutharsan, R. P. Vonberg, A. K. Weber and J. Zerlik	Original	https://pubmed.ncbi.nlm.nih.gov/38350639/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2182-1907	Cystic Fibrosis (CF) is the most common autosomal recessive genetic multisystemic disease. In Germany, it affects at least 8000 people. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the airway epithelial lining fluid which leads to reduction of the mucociliary clearance.Even if highly effective, CFTR modulator therapy has been available for some years and people with CF are getting much older than before, recurrent and chronic infections of the airways as well as pulmonary exacerbations still occur. In adult CF life, Pseudomonas aeruginosa (PA) is the most relevant pathogen in colonisation and chronic infection of the lung, leading to further loss of lung function. There are many possibilities to treat PA-infection.This is a S3-clinical guideline which implements a definition for chronic PA-infection and demonstrates evidence-based diagnostic methods and medical treatment in order to give guidance for individual treatment options.
51.654	European guidelines on perinatal care: corticosteroids for women at risk of preterm birth	10.1080/14767058.2022.2160628	General Lung and Other	JLU	UGMLC	H. Ehrhardt	international	2023		G. Daskalakis, V. Pergialiotis, M. Domellöf, H. Ehrhardt, G. C. Di Renzo, E. Koç, A. Malamitsi-Puchner, M. Kacerovsky, N. Modi, A. Shennan, D. Ayres-de-Campos, E. Gliozheni, K. Rull, T. Braun, A. Beke, K. Kosi?ska-Kaczy?ska, A. L. Areia, S. Vladareanu, T. P. Sršen, T. Schmitz and B. Jacobsson	Original	https://pubmed.ncbi.nlm.nih.gov/36689999/	https://www.tandfonline.com/doi/full/10.1080/14767058.2022.2160628	of recommendationsCorticosteroids should be administered to women at a gestational age between 24(+0) and 33(+6 )weeks, when preterm birth is anticipated in the next seven days, as these have been consistently shown to reduce neonatal mortality and morbidity. (Strong-quality evidence; strong recommendation). In selected cases, extension of this period up to 34(+6 )weeks may be considered (Expert opinion). Optimal benefits are found in infants delivered within 7 days of corticosteroid administration. Even a single-dose administration should be given to women with imminent preterm birth, as this is likely to improve neurodevelopmental outcome (Moderate-quality evidence; conditional recommendation).Either betamethasone (12 mg administered intramuscularly twice, 24-hours apart) or dexamethasone (6 mg administered intramuscularly in four doses, 12-hours apart, or 12 mg administered intramuscularly twice, 24-hours apart), may be used (Moderate-quality evidence; Strong recommendation). Administration of two "all" doses is named a "course of corticosteroids".Administration between 22(+0) and 23(+6 )weeks should be considered when preterm birth is anticipated in the next seven days and active newborn life-support is indicated, taking into account parental wishes. Clear survival benefit has been observed in these cases, but the impact on short-term neurological and respiratory function, as well as long-term neurodevelopmental outcome is still unclear (Low/moderate-quality evidence; Weak recommendation).Administration between 34 + 0 and 34 + 6 weeks should only be offered to a few selected cases (Expert opinion). Administration between 35(+0) and 36(+6 )weeks should be restricted to prospective randomized trials. Current evidence suggests that although corticosteroids reduce the incidence of transient tachypnea of the newborn, they do not affect the incidence of respiratory distress syndrome, and they increase neonatal hypoglycemia. Long-term safety data are lacking (Moderate quality evidence; Conditional recommendation).Administration in pregnancies beyond 37(+0 )weeks is not indicated, even for scheduled cesarean delivery, as current evidence does not suggest benefit and the long-term effects remain unknown (Low-quality evidence; Conditional recommendation).Administration should be given in twin pregnancies, with the same indication and doses as for singletons. However, existing evidence suggests that it should be reserved for pregnancies at high-risk of delivering within a 7-day interval (Low-quality evidence; Conditional recommendation). Maternal diabetes mellitus is not a contraindication to the use of antenatal corticosteroids (Moderate quality evidence; Strong recommendation).A single repeat course of corticosteroids can be considered in pregnancies at less than 34(+0 )weeks gestation, if the previous course was completed more than seven days earlier, and there is a renewed risk of imminent delivery (Low-quality evidence; Conditional recommendation).
51.655	International consensus statement on allergy and rhinology: Allergic rhinitis - 2023	10.1002/alr.23090	AA	BREATH	ITEM	J. M. Hohlfeld	international	2023		S. K. Wise, C. Damask, L. T. Roland, C. Ebert, J. M. Levy, S. Lin, A. Luong, K. Rodriguez, A. R. Sedaghat, E. Toskala, J. Villwock, B. Abdullah, C. Akdis, J. A. Alt, I. J. Ansotegui, A. Azar, F. Baroody, M. S. Benninger, J. Bernstein, C. Brook, R. Campbell, T. Casale, M. Chaaban, F. T. Chew, J. Chambliss, A. Cianferoni, A. Custovic, E. M. Davis, J. M. DelGaudio, A. K. Ellis, C. Flanagan, W. J. Fokkens, C. Franzese, M. Greenhawt, A. Gill, A. Halderman, J. M. Hohlfeld, C. Incorvaia, S. A. Joe, S. Joshi, M. E. Kuruvilla, J. Kim, A. M. Klein, H. J. Krouse, E. C. Kuan, D. Lang, D. Larenas-Linnemann, A. M. Laury, M. Lechner, S. E. Lee, V. S. Lee, P. Loftus, S. Marcus, H. Marzouk, J. Mattos, E. McCoul, E. Melen, J. W. Mims, J. Mullol, J. V. Nayak, J. Oppenheimer, R. R. Orlandi, K. Phillips, M. Platt, M. Ramanathan, Jr., M. Raymond, C. S. Rhee, S. Reitsma, M. Ryan, J. Sastre, R. J. Schlosser, T. A. Schuman, M. S. Shaker, A. Sheikh, K. A. Smith, M. B. Soyka, M. Takashima, M. Tang, P. Tantilipikorn, M. B. Taw, J. Tversky, M. A. Tyler, M. C. Veling, D. Wallace, Y. Wang, A. White and L. Zhang	Review	https://pubmed.ncbi.nlm.nih.gov/36878860/	https://onlinelibrary.wiley.com/doi/10.1002/alr.23090	BACKGROUND: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR-Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence-based findings and recommendation from the full document. METHODS: ICAR-Allergic Rhinitis 2023 employed established evidence-based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. RESULTS: ICAR-Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. CONCLUSION: The ICAR-Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
51.656	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(†)	10.1016/j.annonc.2022.12.013	LC	Ghd	ARCN	M. Reck	international	2023		L. E. Hendriks, K. M. Kerr, J. Menis, T. S. Mok, U. Nestle, A. Passaro, S. Peters, D. Planchard, E. F. Smit, B. J. Solomon, G. Veronesi and M. Reck	Original	https://pubmed.ncbi.nlm.nih.gov/36669645/	https://www.sciencedirect.com/science/article/pii/S0923753422047858?via%3Dihub	No abstract available.
51.657	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up	10.1016/j.annonc.2022.12.009	LC	Ghd	ARCN	M. Reck	international	2023		L. E. Hendriks, K. M. Kerr, J. Menis, T. S. Mok, U. Nestle, A. Passaro, S. Peters, D. Planchard, E. F. Smit, B. J. Solomon, G. Veronesi and M. Reck	Original	https://pubmed.ncbi.nlm.nih.gov/36872130/	https://www.sciencedirect.com/science/article/pii/S0923753422047810?via%3Dihub	No abstract available.
51.658	S2k-Guideline SARS-CoV-2, COVID-19 and (early) rehabilitation - a consensus-based guideline for Germany	10.3205/dgkh000438	ALI	UMR	UGMLC	R. Koczulla	international	2023		T. Platz, P. Berlit, C. Dohle, H. Fickenscher, M. Guha, V. Köllner, A. Kramer, R. Koczulla and A. Schlitt	Original	https://pubmed.ncbi.nlm.nih.gov/37261059/	https://www.egms.de/static/en/journals/dgkh/2023-18/dgkh000438.shtml	The consensus-based guideline "SARS-CoV-2, COVID-19 and (early) rehabilitation" for Germany has two sections: In the first part, the guideline addresses infection protection-related procedures during the COVID-19 pandemic. In the second part, it provides practice recommendations for rehabilitation after COVID-19. The specific recommendations for rehabilitation after COVID-19 as issued by 13 German medical societies and two patient-representative organizations are presented together with general background information for their development.
51.659	The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	10.1093/eurheartj/ehad018	PH	MHH	BREATH	M. M. Hoeper	international	2023		S. Rosenkranz, M. Delcroix, G. Giannakoulas, M. M. Hoeper, G. Kovacs and M. Humbert	Original	https://pubmed.ncbi.nlm.nih.gov/36723982/	https://academic.oup.com/eurheartj/article/44/10/792/7022121?login=true	No abstract available.
51.660	Update of European Society of Clinical Microbiology and Infectious Diseases coronavirus disease 2019 guidelines: diagnostic testing for severe acute respiratory syndrome coronavirus 2	10.1016/j.cmi.2023.04.019	ALI	UMR	UGMLC	C. Skevaki*	international	2023		P. C. Fragkou, G. De Angelis, G. Menchinelli, F. Can, F. Garcia, F. Morfin-Sherpa, D. Dimopoulou, K. Dimopoulou, S. Zelli, A. de Salazar, R. Reiter, H. Janocha, A. Grossi, J. Omony and C. Skevaki	Original	https://pubmed.ncbi.nlm.nih.gov/37088423/	https://www.sciencedirect.com/science/article/pii/S1198743X23001921?via%3Dihub	SCOPE: Since the onset of COVID-19, several assays have been deployed for the diagnosis of SARS-CoV-2. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first set of guidelines on SARS-CoV-2 in vitro diagnosis in February 2022. Because the COVID-19 landscape is rapidly evolving, the relevant ESCMID guidelines panel releases an update of the previously published recommendations on diagnostic testing for SARS-CoV-2. This update aims to delineate the best diagnostic approach for SARS-CoV-2 in different populations based on current evidence. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. The panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the population, intervention, comparison, and outcome (PICO) format was developed at the beginning of the process. For each PICO, 2 panel members performed a literature search focusing on systematic reviews with a third panellist involved in case of inconsistent results. The panel reassessed the PICOs previously defined as priority in the first set of guidelines and decided to address 49 PICO questions, because 6 of them were discarded as outdated/non-clinically relevant. The 'Grading of Recommendations Assessment, Development and Evaluation (GRADE)-adoption, adaptation, and de novo development of recommendations (ADOLOPMENT)' evidence-to-decision framework was used to produce the guidelines. QUESTIONS ADDRESSED BY THE GUIDELINES AND RECOMMENDATIONS: After literature search, we updated 16 PICO questions; these PICOs address the use of antigen-based assays among symptomatic and asymptomatic patients with different ages, COVID-19 severity status or risk for severe COVID-19, time since the onset of symptoms/contact with an infectious case, and finally, types of biomaterials used.
51.662	[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa]	10.1055/a-2278-6685	CFBE	KUM, MHH, RKU	BREATH, CPC-M, TLRC	M. O. Wielpütz, J. Ley-Zaporozhan, F. C. Ringshausen, O. Sommerburg	national	2024		C. Schwarz, J. Bend, H. Hebestreit, M. Hogardt, C. Hügel, S. Illing, J. G. Mainz, E. Rietschel, S. Schmidt, B. Schulte-Hubbert, H. Sitter, M. O. Wielpütz, J. Hammermann, I. Baumann, F. Brunsmann, D. Dieninghoff, E. Eber, H. Ellemunter, P. Eschenhagen, C. Evers, S. Gruber, A. Koitschev, J. Ley-Zaporozhan, U. Düesberg, H. J. Mentzel, T. Nüßlein, F. C. Ringshausen, L. Sedlacek, C. Smaczny, O. Sommerburg, S. Sutharsan, R. P. Vonberg, A. K. Weber and J. Zerlik	Other	https://pubmed.ncbi.nlm.nih.gov/38423036/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2278-6685	No abstract available.
51.663	[Diagnosis and Treatment of Hypersensitivity Pneumonitis - S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology]	10.1055/a-2369-8458	DPLD	KUM, MHH	BREATH. CPC-M	J. Behr, D. Jonigk, D. Nowak	national	2024		D. Koschel, J. Behr, M. Berger, F. Bonella, O. Hamer, M. Joest, D. Jonigk, M. Kreuter, G. Leuschner, D. Nowak, M. Raulf, B. Rehbock, J. Schreiber, H. Sitter, D. Theegarten and U. Costabel	Original	https://pubmed.ncbi.nlm.nih.gov/39227017/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2369-8458	Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD) in sensitized individuals caused by a large variety of inhaled antigens. The clinical form of acute HP is often misdiagnosed, while the chronic form, especially the chronic fibrotic HP, is difficult to differentiate from other fibrotic ILDs. The present guideline for the diagnosis and treatment of HP replaces the former German recommendations for the diagnosis of HP from 2007 and is amended explicitly by the issue of the chronic fibrotic form, as well as by treatment recommendations for the first time. The evidence was discussed by a multidisciplinary committee of experts. Then, recommendations were formulated for twelve questions on important issues of diagnosis and treatment strategies. Recently published national and international guidelines for ILDs and HP were considered. Detailed background information on HP is useful for a deeper insight into HP and the handling of the guideline.
51.642	[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]	10.1055/a-2043-4482	DPLD	ITEM, JLU, KUM, MHH, Thorax	BREATH, CPC-M, TLRC, UGMLC	J. Behr, A. Günther, D. Nowak, A. Prasse	national	2023		J. Behr, F. Bonella, B. C. Frye, A. Günther, L. Hagmeyer, J. Henes, P. Klemm, D. Koschel, M. Kreuter, G. Leuschner, D. Nowak, A. Prasse, B. Quadder, H. Sitter and U. Costabel	Other	https://pubmed.ncbi.nlm.nih.gov/36858353/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2043-4482	No abstract available.
51.643	[Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]	10.1055/a-2029-0134	LC	Ghd, KUM, Thorax	ARCN, CPC-M, TLRC	P. Christopoulos, H. U. Kauczor, M. Reck, N. Reinmuth, M. Thomas, A. Tufman	national	2023		W. Schütte, S. Gütz, W. Nehls, T. G. Blum, W. Brückl, N. Buttmann-Schweiger, R. Büttner, P. Christopoulos, S. Delis, K. M. Deppermann, N. Dickgreber, W. Eberhardt, S. Eggeling, J. Fleckenstein, M. Flentje, N. Frost, F. Griesinger, C. Grohé, A. Gröschel, M. Guckenberger, E. Hecker, H. Hoffmann, R. M. Huber, K. Junker, H. U. Kauczor, J. Kollmeier, K. Kraywinkel, M. Krüger, C. Kugler, M. Möller, U. Nestle, B. Passlick, J. Pfannschmidt, M. Reck, N. Reinmuth, C. Rübe, R. Scheubel, C. Schumann, M. Sebastian, M. Serke, E. Stoelben, M. Stuschke, M. Thomas, A. Tufman, D. Vordermark, C. Waller, J. Wolf, M. Wolf and D. Wormanns	Original	https://pubmed.ncbi.nlm.nih.gov/37884003/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2029-0134	The current S3 Lung Cancer Guidelines are edited with fundamental changes to the previous edition based on the dynamic influx of information to this field:The recommendations include de novo a mandatory case presentation for all patients with lung cancer in a multidisciplinary tumor board before initiation of treatment, furthermore CT-Screening for asymptomatic patients at risk (after federal approval), recommendations for incidental lung nodule management , molecular testing of all NSCLC independent of subtypes, EGFR-mutations in resectable early stage lung cancer in relapsed or recurrent disease, adjuvant TKI-therapy in the presence of common EGFR-mutations, adjuvant consolidation treatment with checkpoint inhibitors in resected lung cancer with PD-L1 ≥ 50%, obligatory evaluation of PD-L1-status, consolidation treatment with checkpoint inhibition after radiochemotherapy in patients with PD-L1-pos. tumor, adjuvant consolidation treatment with checkpoint inhibition in patients withPD-L1 ≥ 50% stage IIIA and treatment options in PD-L1 ≥ 50% tumors independent of PD-L1status and targeted therapy and treatment option immune chemotherapy in first line SCLC patients.Based on the current dynamic status of information in this field and the turnaround time required to implement new options, a transformation to a "living guideline" was proposed.
51.641	[Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis - S2k Guideline of the German Respiratory Society]	10.1055/a-1983-6796	DPLD	ITEM, JLU, KUM, MHH, Thorax	BREATH, CPC-M, TLRC, UGMLC	J. Behr, A. Günther, D. Nowak, A. Prasse	national	2023		J. Behr, F. Bonella, B. C. Frye, A. Günther, L. Hagmeyer, J. Henes, P. Klemm, D. Koschel, M. Kreuter, G. Leuschner, D. Nowak, A. Prasse, B. Quadder, H. Sitter and U. Costabel	Original	https://pubmed.ncbi.nlm.nih.gov/36791790/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1983-6796	No abstract available.
51.624	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	10.1093/eurheartj/ehac237	PH	JLU, MHH	BREATH, UGMLC	M. M. Hoeper, H. A. Ghofrani, K. M. Olsson	international	2022		M. Humbert, G. Kovacs, M. M. Hoeper, R. Badagliacca, R. M. F. Berger, M. Brida, J. Carlsen, A. J. S. Coats, P. Escribano-Subias, P. Ferrari, D. S. Ferreira, H. A. Ghofrani, G. Giannakoulas, D. G. Kiely, E. Mayer, G. Meszaros, B. Nagavci, K. M. Olsson, J. Pepke-Zaba, J. K. Quint, G. Rådegran, G. Simonneau, O. Sitbon, T. Tonia, M. Toshner, J. L. Vachiery, A. Vonk Noordegraaf, M. Delcroix and S. Rosenkranz	Original	https://pubmed.ncbi.nlm.nih.gov/36017548/	https://academic.oup.com/eurheartj/article/43/38/3618/6673929?login=false	No abstract available.
51.625	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension	10.1002/pul2.12127	DPLD, PH	JLU	UGMLC	M. J. Richter	international	2022		S. M. Nikkho, M. J. Richter, E. Shen, S. H. Abman, K. Antoniou, J. Chung, P. Fernandes, P. Hassoun, H. M. Lazarus, H. Olschewski, L. Piccari, M. Psotka, R. Saggar, O. A. Shlobin, N. Stockbridge, P. Vitulo, C. D. Vizza, S. J. Wort and S. D. Nathan	Review	https://pubmed.ncbi.nlm.nih.gov/36016668/	https://onlinelibrary.wiley.com/doi/10.1002/pul2.12127	Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity, an increased risk of hospitalizations and death. Examining the scope of this issue and its impact on patients is the first step in trying to define a roadmap to facilitate and encourage future research in this area. The aim of our working group is to strengthen the communities understanding of PH due to lung diseases and to improve the care and quality of life of affected patients. This introductory statement provides a broad overview and lays the foundation for further in-depth papers on specific topics pertaining to PH-ILD.
51.626	DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis	10.1007/s00066-022-01994-3	LC	Throax	TLRC	M. Thomas	national	2022		D. Bernhardt, L. König, A. Grosu, B. Wiestler, S. Rieken, W. Wick, J. Gempt, S. M. Krieg, F. Schmidt-Graf, F. Sahm, B. Meyer, B. J. Krause, C. Petersen, R. Fietkau, M. Thomas, F. Giordano, A. Wittig-Sauerwein, J. Debus, G. Tabatabai, P. Hau, J. Steinbach and S. E. Combs	Review	https://pubmed.ncbi.nlm.nih.gov/36038669/	https://link.springer.com/article/10.1007/s00066-022-01994-3	PURPOSE: The Working Group for Neuro-Oncology of the German Society for Radiation Oncology in cooperation with members of the Neuro-Oncology Working Group of the German Cancer Society aimed to define a practical guideline for the diagnosis and treatment of radiation-induced necrosis (RN) of the central nervous system (CNS). METHODS: Panel members of the DEGRO working group invited experts, participated in a series of conferences, supplemented their clinical experience, performed a literature review, and formulated recommendations for medical treatment of RN including bevacizumab in clinical routine. CONCLUSION: Diagnosis and treatment of RN requires multidisciplinary structures of care and defined processes. Diagnosis has to be made on an interdisciplinary level with the joint knowledge of a neuroradiologist, radiation oncologist, neurosurgeon, neuropathologist, and neuro-oncologist. A multistep approach as an opportunity to review as many characteristics as possible to improve diagnostic confidence is recommended. Additional information about radiotherapy (RT) techniques is crucial for the diagnosis of RN. Misdiagnosis of untreated and progressive RN can lead to severe neurological deficits. In this practice guideline, we propose a detailed nomenclature of treatment-related changes and a multistep approach for their diagnosis.
51.627	DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment	10.1007/s00066-022-01973-8	LC	Thorax	TLRC	M. Thomas	national	2022		D. Bernhardt, L. König, A. L. Grosu, S. Rieken, S. M. Krieg, W. Wick, B. Wiestler, F. Schmidt-Graf, F. Sahm, J. Gempt, B. Meyer, B. J. Krause, C. Petersen, R. Fietkau, M. Thomas, F. Giordano, A. Wittig-Sauerwein, J. Debus, G. Tabatabai, P. Hau, J. Steinbach and S. E. Combs	Review	https://pubmed.ncbi.nlm.nih.gov/36038670/	https://link.springer.com/article/10.1007/s00066-022-01973-8	PURPOSE: The Working Group for Neurooncology of the German Society for Radiation Oncology (DEGRO; AG NRO) in cooperation with members of the Neurooncological Working Group of the German Cancer Society (DKG-NOA) aimed to define a practical guideline for the diagnosis and treatment of radiation-induced necrosis (RN) of the central nervous system (CNS). METHODS: Panel members of the DEGRO working group invited experts, participated in a series of conferences, supplemented their clinical experience, performed a literature review, and formulated recommendations for medical treatment of RN, including bevacizumab, in clinical routine. CONCLUSION: Diagnosis and treatment of RN requires multidisciplinary structures of care and defined processes. Diagnosis has to be made on an interdisciplinary level with the joint knowledge of a neuroradiologist, radiation oncologist, neurosurgeon, neuropathologist, and neurooncologist. If the diagnosis of blood-brain barrier disruptions (BBD) or RN is likely, treatment should be initiated depending on the symptoms, location, and dynamic of the lesion. Multiple treatment options are available (such as observation, surgery, steroids, and bevacizumab) and the optimal approach should be discussed in an interdisciplinary setting. In this practice guideline, we offer detailed treatment strategies for various scenarios.
51.628	Early priming of asthma and respiratory allergies: Future aspects of prevention: A statement by the European Forum for Education and Research in Allergy and Airway Disease (EUFOREA) and the EAACI-Clemens von Pirquet Foundation	10.1111/pai.13773	AA	CAU, KUM	ARCN, CPC-M	S. Krauss-Etschmann, B. Schaub, M. Ege, E. von Mutius	international	2022		U. Wahn, S. Lau, P. Eigenmann, E. Melen, S. Krauss-Etschmann, C. Lex, P. Matricardi, B. Schaub, S. Halken, M. Ege, D. Jackson, E. Hamelmann, Z. Szépfalusi, A. N. Garcia and E. von Mutius	Original	https://pubmed.ncbi.nlm.nih.gov/35470937/	https://onlinelibrary.wiley.com/doi/10.1111/pai.13773	In order to summarize recent research on the prevention of allergies-particularly asthma-and stimulate new activities for future initiatives, a virtual workshop sponsored by the EAACI Clemens von Pirquet foundation and EUFOREA was held in October 2021. The determinants of the "allergic march" as well as the key messages from intervention studies were reviewed by an international faculty of experts. Several unmet needs were identified, and a number of priorities for future studies were proposed.
51.629	ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2	10.1016/j.cmi.2022.02.011	ALI	UMR	UGMLC	C. Skevaki*	international	2022		P. C. Fragkou, G. De Angelis, G. Menchinelli, F. Can, F. Garcia, F. Morfin-Sherpa, D. Dimopoulou, E. Mack, A. de Salazar, A. Grossi, T. Lytras and C. Skevaki	Original	https://pubmed.ncbi.nlm.nih.gov/35218978/	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00084-2/fulltext	SCOPE: The objective of these guidelines is to identify the most appropriate diagnostic test and/or diagnostic approach for SARS-CoV-2. The recommendations are intended to provide guidance to clinicians, clinical microbiologists, other health care personnel, and decision makers. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search focusing on systematic reviews with a third panelist involved in case of inconsistent results. Quality of evidence assessment was based on the GRADE-ADOLOPMENT approach. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: A total of 43 PICO questions were selected that involve the following types of populations: 1) patients with signs and symptoms of COVID-19; 2) travelers, healthcare workers, and other individuals at risk for exposure to SARS-CoV-2; 3) asymptomatic individuals and 4) close contacts of patients infected with SARS-CoV-2. The type of diagnostic test (commercial rapid nucleic acid amplification tests, and rapid antigen detection), biomaterial, time since onset of symptoms/contact with an infectious case, age, disease severity, and risk of developing severe disease are also taken into consideration.
51.630	European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials	10.1183/13993003.00300-2022	CFBE	KUM	CPC-M	M. Griese	international	2022		A. B. Chang, A. Zacharasiewicz, V. Goyal, J. Boyd, E. Alexopoulou, S. Aliberti, L. Bell, A. Bush, A. Claydon, C. Constant, R. Fortescue, A. T. Hill, B. Karadag, Z. Powell, C. Wilson, K. Grimwood, A. Kantar, B.-N. other members of Child, J. Chalmers, A. Collaro, K. Douros, M. Griese, J. Grigg, A. Hector, O. Mazulov, F. Midulla, A. Moller, M. Proesmans and S. Yerkovich	Review	https://www.ncbi.nlm.nih.gov/pubmed/35728974	https://publications.ersnet.org/content/erj/60/5/2200300	Bronchiectasis is being diagnosed increasingly in children and adolescents. Recurrent respiratory exacerbations are common in children and adolescents with this chronic pulmonary disorder. Respiratory exacerbations are associated with an impaired quality of life, poorer long-term clinical outcomes, and substantial costs to the family and health systems. The 2021 European Respiratory Society (ERS) clinical practice guideline for the management of children and adolescents with bronchiectasis provided a definition of acute respiratory exacerbations for clinical use but to date there is no comparable universal definition for clinical research. Given the importance of exacerbations in the field, this ERS Task Force sought to obtain robust definitions of respiratory exacerbations for clinical research. The panel was a multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, methodology, patient advocacy, and parents of children and adolescents with bronchiectasis. We used a standardised process that included a systematic literature review, parent survey, and a Delphi approach involving 299 physicians (54 countries) caring for children and adolescents with bronchiectasis. Consensus was obtained for all four statements drafted by the panel as the disagreement rate was very low (range 3.6-7.2%). The panel unanimously endorsed the four consensus definitions for 1a) non-severe exacerbation and 1b) severe exacerbation as an outcome measure, 2) non-severe exacerbation for studies initiating treatment, and 3) resolution of a non-severe exacerbation for clinical trials involving children and adolescents with bronchiectasis. This ERS Task Force proposes using these internationally derived, consensus-based definitions of respiratory exacerbations for future clinical paediatric bronchiectasis research.
51.631	European Respiratory Society Statement on Familial Pulmonary Fibrosis	10.1183/13993003.01383-2022	DPLD	KUM, MHH	BREATH, CPC-M	M. Griese, A. Prasse	international	2022		R. Borie, C. Kannengiesser, K. Antoniou, F. Bonella, B. Crestani, A. Fabre, A. Froidure, L. Galvin, M. Griese, J. C. Grutters, M. Molina-Molina, V. Poletti, A. Prasse, E. Renzoni, J. van der Smagt and C. H. M. van Moorsel	Original	https://pubmed.ncbi.nlm.nih.gov/36549714/	https://publications.ersnet.org/content/erj/61/3/2201383	Genetic predisposition to pulmonary fibrosis has been confirmed by the discovery of several gene mutations that cause pulmonary fibrosis. Although genetic sequencing of familial pulmonary fibrosis (FPF) cases is embedded in routine clinical practice in several countries, many centers have yet to incorporate genetic sequencing within ILD services, and proper international consensus has not yet been established.An international and multidisciplinary expert taskforce (pulmonologists, geneticists, pediatrician, pathologist, genetic counselor, patient representative, and librarian) reviewed the literature between 1945 and 2022, and reached consensus for all of the following questions: 1) Which patients may benefit from genetic sequencing and clinical counseling? 2) What is known of the natural history of familial disease? 3) Which genes are usually tested? 4) What is the evidence for telomere length measurement? 5) What is the role of common genetic variants (polymorphisms) in the diagnostic workup? 6) What are the optimal treatment options for FPF? 7) Which family members are eligible for genetic sequencing? 8) Which clinical screening and follow-up parameters may be considered in family members?Through a robust review of the literature, the panel offers a statement on genetic sequencing, clinical management and screening of patients with FPF and their relatives. This proposal may serve as a basis for a prospective evaluation and future international recommendations.
51.632	Genetic counselling and testing in pulmonary arterial hypertension -A consensus statement on behalf of the International Consortium for Genetic Studies in PAH	10.1183/13993003.01471-2022	PH	JLU, Thorax	TLRC, UGMLC	C. A. Eichstaedt, E. Grünig, H. A. Ghofrani, W. Seeger, N. Sommer	international	2022		C. A. Eichstaedt, C. Belge, W. K. Chung, S. Gräf, E. Grünig, D. Montani, R. Quarck, J. A. Tenorio-Castano, F. Soubrier, R. C. Trembath and N. W. Morrell	Original	https://pubmed.ncbi.nlm.nih.gov/36302552/	https://publications.ersnet.org/content/erj/61/2/220147	Pulmonary arterial hypertension (PAH) is a rare disease, which can be caused by (likely) pathogenic germline genomic variants. In addition to the most prevalent disease gene, termed bone morphogenetic protein receptor 2 (BMPR2), several genes, some belonging to distinct functional classes, are also now known to predispose to the development of PAH. As a consequence, specialist and non-specialist clinicians and health care professionals, are increasingly faced with a range of questions regarding the need for, approaches to and the benefits and risks, of genetic testing for PAH patients and/or related family members. We provide a consensus-based approach to recommendations for genetic counselling and assessment of current best practice for disease gene testing. We provide a framework and the type of information to be provided to patients and relatives, through the process of genetic counselling, and describe the presently known disease causal genes, to be analysed. Benefits of including molecular genetic testing within the management protocol of patients with PAH, include identification of individuals misclassified by other diagnostic approaches, the optimisation of phenotypic characterisation for aggregation of outcome data, including in clinical trials and importantly through cascade screening, the detection of healthy causal variant carriers, to whom regular assessment should be offered.
51.634	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians	10.1159/000518896	AA, ALI, CF, COPD, DPLD, LC, General Lung and Other	ASK, Ghd, MHH, Thorax, UMR	ARCN, BREATH, CPC-M, TLRC, UGMLC	K. F. Rabe, F. C. Ringshausen, C. F. Vogelmeier, N. Reinmuth, M. Reck, J. Gottlieb, T. Welte	national	2022		M. Lommatzsch, K. F. Rabe, C. Taube, M. Joest, M. Kreuter, H. Wirtz, T. G. Blum, M. Kolditz, H. Geerdes-Fenge, R. Otto-Knapp, B. Häcker, T. Schaberg, F. C. Ringshausen, C. F. Vogelmeier, N. Reinmuth, M. Reck, J. Gottlieb, S. Konstantinides, J. Meyer, H. Worth, W. Windisch, T. Welte and T. Bauer	Original	https://pubmed.ncbi.nlm.nih.gov/35231915/	https://karger.com/res/article/101/3/307/826624/Risk-Assessment-for-Patients-with-Chronic	Assessing the risk for specific patient groups to suffer from severe courses of COVID-19 is of major importance in the current SARS-CoV-2 pandemic. This review focusses on the risk for specific patient groups with chronic respiratory conditions, such as patients with asthma, chronic obstructive pulmonary disease, cystic fibrosis (CF), sarcoidosis, interstitial lung diseases, lung cancer, sleep apnea, tuberculosis, neuromuscular diseases, a history of pulmonary embolism, and patients with lung transplants. Evidence and recommendations are detailed in exemplary cases. While some patient groups with chronic respiratory conditions have an increased risk for severe courses of COVID-19, an increasing number of studies confirm that asthma is not a risk factor for severe COVID-19. However, other risk factors such as higher age, obesity, male gender, diabetes, cardiovascular diseases, chronic kidney or liver disease, cerebrovascular and neurological disease, and various immunodeficiencies or treatments with immunosuppressants need to be taken into account when assessing the risk for severe COVID-19 in patients with chronic respiratory diseases.
51.635	S3 Guideline "Smoking and Tobacco Dependence: Screening, Diagnosis, and Treatment" - Short Version	10.1159/000525265	General Lung and Other	JLU	UGMLC	S. Andreas	national	2022		A. Batra, F. Kiefer, S. Andreas, H. Gohlke, M. Klein, D. Kotz, U. Mons, S. Mühlig, M. Pötschke-Langer, U. W. Preuss, T. Rüther, C. Rustler, R. Thomasius, S. Ulbricht and K. U. Petersen	Original	https://pubmed.ncbi.nlm.nih.gov/35760048/	https://karger.com/ear/article/28/5/382/823438/S3-Guideline-Smoking-and-Tobacco-Dependence	INTRODUCTION: In addition to the prevention of tobacco consumption, the establishment and assurance of high-quality treatment for harmful use and dependence on tobacco products remains an important health-related task in Germany. Regular updating of the Association of the Scientific Medical Societies (AWMF) S3 guideline "Smoking and Tobacco Dependence: Screening, Diagnosis, and Treatment" (Tobacco Guideline) offers a sustainable and reputable source of knowledge on smoking cessation. METHODS: Under the auspices of the German Society for Psychiatry, Psychotherapy, Psychosomatics, and Neurology (DGPPN) and the German Society for Addiction Research and Addiction Therapy (DG-Sucht), the Tobacco Guideline was revised in 2019-2020 by 63 experts, who were involved in the development process of the text, in 11 working groups. Undue influence of conflicts of interest on the guideline could be minimized through careful conflict of interest management. Delegates from 50 professional societies discussed the 80 guideline recommendations and voted online. RESULTS: In addition to recommendations for screening and diagnostics, the Tobacco Guideline takes a positive stance towards the use of low-threshold counseling and support services. If, due to the severity of the tobacco-related disorder, brief counseling, telephone counseling, or internet- or smartphone-based methods are not sufficiently effective, individual or group behavioral therapy, possibly in combination with medication, is indicated. If nicotine replacement therapy is not effective, varenicline or bupropion should be offered. Alternative strategies with a lower level of recommendation are hypnotherapy, mindfulness-based treatments, or medication with cytisine. In adolescents and pregnant women, the use of medication should be limited to well-specified exceptions and nicotine replacement. The mean agreement with the recommendations reached a value of 98%. A general overview of the treatment recommendations of the Tobacco Guideline is provided by three clinical algorithms.
51.636	S3 guideline Allergy Prevention	10.5414/alx02303e	AA	KUM, UzL	ARCN, CPC-M	M. V. Kopp, B. Schaub	international	2022		M. V. Kopp, C. Muche-Borowski, M. Abou-Dakn, B. Ahrens, K. Beyer, K. Blümchen, P. Bubel, A. Chaker, M. Cremer, R. Ensenauer, M. Gerstlauer, U. Gieler, I. M. Hübner, F. Horak, L. Klimek, B. V. Koletzko, S. Koletzko, S. Lau, T. Lob-Corzilius, K. Nemat, E. M. J. Peters, A. Pizzulli, I. Reese, C. Rolinck-Werninghaus, E. Rouw, B. Schaub, S. Schmidt, J. O. Steiß, A. K. Striegel, Z. Szépfalusi, D. Schlembach, T. Spindler, C. Taube, V. Trendelenburg, R. Treudler, U. Umpfenbach, C. Vogelberg, M. Wagenmann, A. Weißenborn, T. Werfel, M. Worm, H. Sitter and E. Hamelmann	Original	https://pubmed.ncbi.nlm.nih.gov/35274076/	https://www.dustri.com/article_response_page.html?artId=189264&doi=10.5414/ALX02303E&L=0	BACKGROUND: The persistently high prevalence of allergic diseases in Western industrial nations and the limited possibilities of causal therapy make evidence-based recommendations for primary prevention necessary. METHODS: The recommendations of the S3 guideline Allergy Prevention, published in its last version in 2014, were revised and consulted on the basis of a current systematic literature search. The evidence search was conducted for the period 06/2013 - 11/2020 in the electronic databases Cochrane and MEDLINE, as well as in the reference lists of current reviews and through references from experts. The literature found was screened in two filtering processes, first by title and abstract, and the remaining papers were screened in the full text for relevance. The studies included after this were sorted by level of evidence, and the study quality was indicated in terms of potential bias (low/high). The revised recommendations were formally agreed and consented upon with the participation of representatives of the relevant professional societies and (self-help) organizations (nominal group process). Of 5,681 hits, 286 studies were included and assessed. RESULTS: Recommendations on maternal nutrition during pregnancy and breastfeeding as well as on infant nutrition in the first months of life again play an important role in the updated guideline: Many of the previous recommendations were confirmed by the current data. It was specified that breastfeeding should be exclusive for the first 4 - 6 months after birth, if possible, and that breastfeeding should continue with the introduction of complementary foods. A new recommendation is that supplementary feeding of cow's milk-based formula should be avoided in the first days of life if the mother wishes to breastfeed. Furthermore, it was determined that the evidence for a clear recommendation for hydrolyzed infant formula in non-breastfed infants at risk is currently no longer sufficient. It is therefore currently recommended to check whether an infant formula with proven efficacy in allergy prevention studies is available until the introduction of complementary feeding. Finally, based on the EAACI guideline, recommendations were made for the prevention of chicken egg allergy by introducing and regularly giving thoroughly heated (e.g., baked or hard-boiled) but not "raw" chicken egg (also no scrambled egg) with the complementary food. The recommendation to introduce peanut in complementary feeding was formulated cautiously for the German-speaking countries: In families who usually consume peanut, the regular administration of peanut-containing foods in age-appropriate form (e.g., peanut butter) with the complementary diet can be considered for the primary prevention of peanut allergy in infants with atopic dermatitis (AD). Before introduction, a clinically relevant peanut allergy must be ruled out, especially in infants with moderate to severe AD. There is still insufficient evidence for an allergy-preventive efficacy of prebiotics or probiotics, vitamin D, or other vitamins in the form of supplements so that recommendations against their supplementation were adopted for the first time in the current guideline. Biodiversity plays an important role in the development of immunological tolerance to environmental and food allergens: there is clear evidence that growing up on a farm is associated with a lower risk of developing asthma and allergic diseases. This is associated with early non-specific immune stimulation due to, among other things, the greater microbial biodiversity of house dust in this habitat. This aspect is also reflected in the recommendations on animal husbandry, on which a differentiated statement was made: In families without a recognizable increased allergy risk, pet keeping with cats or dogs should not generally be restricted. Families with an increased allergy risk or with children with already existing AD should not acquire a new cat - in contrast, however, dog ownership should not be discouraged. Interventions to reduce exposure to dust mite allergens in the home, such as the use of mite allergen-proof mattress covers ("encasings"), should be restricted to patients with already proven specific sensitization against house dust mite allergen. Children born by caesarean section have a slightly increased risk of asthma - this should be taken into account when advising on mode of delivery outside of emergency situations. Recent work also supports the recommendations on air pollutants: Active and passive exposure to tobacco smoke increase the risk of allergies, especially asthma, and should therefore be avoided. Exposure to nitrogen oxides, ozone, and small particles (PM 2.5) is associated with an increased risk, especially for asthma. Therefore, exposure to emissions of nitrogen oxides, ozone, and small particles (PM 2.5) should be kept low. The authors of this guideline are unanimously in favor of enacting appropriate regulations to minimize
51.637	[Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]	10.1055/a-2017-8971	DPLD	ITEM, JLU, KUM, MHH, Thorax	BREATH, CPC-M, TLRC, UGMLC	J. Behr, C. P. Heussel, D. Jonigk, P. Markart, D. Nowak, A. Prasse, H. Winter	national	2023		M. Kreuter, J. Behr, F. Bonella, U. Costabel, A. Gerber, O. W. Hamer, C. P. Heussel, D. Jonigk, A. Krause, D. Koschel, G. Leuschner, P. Markart, D. Nowak, M. Pfeifer, A. Prasse, J. Wälscher, H. Winter and H. J. Kabitz	Original	https://pubmed.ncbi.nlm.nih.gov/36977470/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2017-8971	The evaluation of a patient with interstitial lung disease (ILD) includes assessment of clinical, radiological, and often histopathological data. As there were no specific recommendations to guide the evaluation of patients under the suspicion of an ILD within the German practice landscape, this position statement from an interdisciplinary panel of ILD experts provides guidance related to the diagnostic modalities which should be used in the evaluation of ILD. This includes clinical assessment rheumatological evaluation, radiological examinations, histopathologic sampling and the need for a final discussion in a multidisciplinary team.
51.638	[Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.]	10.1055/a-2070-2135	AA	Ghd, UMR, Thorax, KUM	ARCN, CPC-M, UGMLC	A. R. Koczulla, K. Milger-Kneidinger, D. Nowak, K. F. Rabe, O. Schmidt, C. F. Vogelmeier	international	2023		M. Lommatzsch, C. P. Criee, C. C. M. de Jong, M. Gappa, C. Gessner, M. Gerstlauer, N. Hamalainen, P. Haidl, E. Hamelmann, F. Horak, M. Idzko, A. Ignatov, A. R. Koczulla, S. Korn, M. Kohler, C. Lex, J. Meister, K. Milger-Kneidinger, D. Nowak, M. Nothacker, O. Pfaar, W. Pohl, A. M. Preisser, K. F. Rabe, J. Riedler, O. Schmidt, J. Schreiber, A. Schuster, M. Schuhmann, T. Spindler, C. Taube, J. Christian Virchow, C. Vogelberg, C. F. Vogelmeier, F. Wantke, W. Windisch, H. Worth, A. Zacharasiewicz, R. Buhl, V. Weitere beteiligte Wissenschaftliche Fachgesellschaften und Organisationen: Deutsche Atemwegsliga e, V. Deutsche Gesellschaft fur Arbeitsmedizin und Umweltmedizin e, V. Deutsche Gesellschaft fur Allergologie und klinische Immunologie e, V. Deutsche Gesellschaft fur Gynakologie und Geburtshilfe e, V. Deutsche Gesellschaft fur Rehabilitationswissenschaften e, V. Gesellschaft fur Padiatrische Allergologie und Umweltmedizin e, V. Gesellschaft fur Padiatrische Pneumologie e, S.-u. B. Bundesverband der Pneumologen, J. Osterreichische Gesellschaft fur Kinder- und, P. Osterreichische Gesellschaft fur and V. Deutsche Patientenliga Atemwegserkrankungen e	Original	https://www.ncbi.nlm.nih.gov/pubmed/37406667	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2070-2135	The management of asthma has fundamentally changed during the past decades. The present guideline for the diagnosis and treatment of asthma was developed for respiratory specialists who need detailed and evidence-based information on the new diagnostic and therapeutic options in asthma. The guideline shows the new role of biomarkers, especially blood eosinophils and fractional exhaled NO (FeNO), in diagnostic algorithms of asthma. Of note, this guideline is the first worldwide to announce symptom prevention and asthma remission as the ultimate goals of asthma treatment, which can be achieved by using individually tailored, disease-modifying anti-asthmatic drugs such as inhaled steroids, allergen immunotherapy or biologics. In addition, the central role of the treatment of comorbidities is emphasized. Finally, the document addresses several challenges in asthma management, including asthma treatment during pregnancy, treatment of severe asthma or the diagnosis and treatment of work-related asthma.
51.639	[Genetic counselling and testing in pulmonary arterial hypertension - A consensus statement on behalf of the International Consortium for Genetic Studies in PAH - French version]	10.1016/j.rmr.2023.10.004	PH	Thorax	TLRC	C. A. Eichstaedt, E. Grünig	international	2023		D. Montani, C. A. Eichstaedt, C. Belge, W. K. Chung, S. Gräf, E. Grünig, M. Humbert, R. Quarck, J. A. Tenorio-Castano, F. Soubrier, R. C. Trembath and N. W. Morrell	Original	https://pubmed.ncbi.nlm.nih.gov/37923650/	https://www.sciencedirect.com/science/article/abs/pii/S0761842523002632?via%3Dihub	Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely) pathogenic germline genomic variants. In addition to the most prevalent disease gene, BMPR2 (bone morphogenetic protein receptor 2), several genes, some belonging to distinct functional classes, are also now known to predispose to the development of PAH. As a consequence, specialist and non-specialist clinicians and healthcare professionals are increasingly faced with a range of questions regarding the need for, approaches to and benefits/risks of genetic testing for PAH patients and/or related family members. We provide a consensus-based approach to recommendations for genetic counselling and assessment of current best practice for disease gene testing. We provide a framework and the type of information to be provided to patients and relatives through the process of genetic counselling, and describe the presently known disease causal genes to be analysed. Benefits of including molecular genetic testing within the management protocol of patients with PAH include the identification of individuals misclassified by other diagnostic approaches, the optimisation of phenotypic characterisation for aggregation of outcome data, including in clinical trials, and importantly through cascade screening, the detection of healthy causal variant carriers, to whom regular assessment should be offered.
51.640	[New aspects in pediatric pulmonary hypertension - Commented 2022ERS/ESC-PH guidelines]	10.1055/a-2145-4832	PH	Thorax	TLRC	C. A. Eichstaedt	international	2023		C. Apitz, R. Kozlik-Feldmann, C. A. Eichstaedt, M. Gorenflo, A. E. Lammers and R. Geiger	Original	https://pubmed.ncbi.nlm.nih.gov/37963484/	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2145-4832	Pulmonary hypertension (PH) in childhood differs from that of adulthood particularly in the specific pathophysiology of congenital heart disease-associated pulmonary arterial hypertension, the presence of developmental lung disease, and the frequent association with chromosomal, genetic, and syndromal abnormalities. Treatment of children with PH requires a modified diagnostic algorithm tailored to childhood, as well as pathophysiologically oriented therapeutic strategies. In the current 2022 ERS/ESC-PH guidelines, the specific features of PH in children are highlighted in its own chapter and commented on by the authorship group in this article.
51.633	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method	10.1016/s1473-3099(21)00626-5	ALI	MHH	BREATH	T. Welte	international	2022		P. Nasa, E. Azoulay, A. Chakrabarti, J. V. Divatia, R. Jain, C. Rodrigues, V. D. Rosenthal, W. Alhazzani, Y. M. Arabi, J. Bakker, M. Bassetti, J. De Waele, G. Dimopoulos, B. Du, S. Einav, L. Evans, S. Finfer, C. Guérin, N. E. Hammond, S. Jaber, R. M. Kleinpell, Y. Koh, M. Kollef, M. M. Levy, F. R. Machado, J. Mancebo, I. Martin-Loeches, M. Mer, M. S. Niederman, P. Pelosi, A. Perner, J. V. Peter, J. Phua, L. Piquilloud, M. W. Pletz, A. Rhodes, M. J. Schultz, M. Singer, J. F. Timsit, B. Venkatesh, J. L. Vincent, T. Welte and S. N. Myatra	Review	https://pubmed.ncbi.nlm.nih.gov/34774188/	https://www.sciencedirect.com/science/article/pii/S1473309921006265?via%3Dihub	During the current COVID-19 pandemic, health-care workers and uninfected patients in intensive care units (ICUs) are at risk of being infected with SARS-CoV-2 as a result of transmission from infected patients and health-care workers. In the absence of high-quality evidence on the transmission of SARS-CoV-2, clinical practice of infection control and prevention in ICUs varies widely. Using a Delphi process, international experts in intensive care, infectious diseases, and infection control developed consensus statements on infection control for SARS-CoV-2 in an ICU. Consensus was achieved for 31 (94%) of 33 statements, from which 25 clinical practice statements were issued. These statements include guidance on ICU design and engineering, health-care worker safety, visiting policy, personal protective equipment, patients and procedures, disinfection, and sterilisation. Consensus was not reached on optimal return to work criteria for health-care workers who were infected with SARS-CoV-2 or the acceptable disinfection strategy for heat-sensitive instruments used for airway management of patients with SARS-CoV-2 infection. Well designed studies are needed to assess the effects of these practice statements and address the remaining uncertainties.
51.542	Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals	10.1055/a-1294-1580	ALI	Ghd, UKSH (Kiel)	Assoziierter Partner, ARCN	R. Diel	national	2021		R. Diel, T. Schaberg, A. Nienhaus, R. Otto-Knapp, C. Kneitz, A. Krause, M. Fabri, U. Mrowietz, T. Bauer and B. Hacker	Original	https://www.ncbi.nlm.nih.gov/pubmed/33598901	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1294-1580	BACKGROUND: While the risk of tuberculosis (TB) reactivation is adequately documented in relation to TNF-alpha inhibitors (TNFi), the question of what the tuberculosis risk is for newer, non-TNF biologics (non-TNFi) has not been thoroughly addressed. METHODS: We conducted a systematic review of randomized phase 2 and phase 3 studies, and long-term extensions of same, published through March 2019. Of interest was information pertaining to screening and treating of latent tuberculosis (LTBI) in association with the use of 12 particular non-TNFi. Only rituximab was excluded. We searched MEDLINE and the ClinicalTrial.gov database for any and all candidate studies meeting these criteria. RESULTS: 677 citations were retrieved; 127 studies comprising a total of 34,293 patients who received non-TNFi were eligible for evaluation. Only 80 out of the 127 studies, or 63 %, captured active TB (or at least opportunistic diseases) as potential outcomes and 25 TB cases were reported. More than two thirds of publications (86/127, 68 %) mentioned LTBI screening prior to inclusion of study participants in the respective trial, whereas in only 4 studies LTBI screening was explicitly considered redundant. In 21 studies, patients with LTBI were generally excluded from the trials and in 42 out of the 127 trials, or 33 %, latently infected patients were reported to receive preventive therapy (PT) at least 3 weeks prior to non-TNFi treatment. CONCLUSIONS: The lack of information in many non-TNFi studies on the number of patients with LTBI who were either excluded prior to participating or had been offered PT hampers assessment of the actual TB risk when applying the novel biologics. Therefore, in case of insufficient information about drugs or drug classes, the existing recommendations of the German Central Committee against Tuberculosis should be applied in the same way as is done prior to administering TNFi. Well designed, long-term "real world" register studies on TB progression risk in relation to individual substances for IGRA-positive cases without prior or concomitant PT may help to reduce selection bias and to achieve valid conclusions in the future.
51.541	Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021	10.1097/ccm.0000000000005357	General Lung and Other	MHH	BREATH	T. Welte	international	2021		L. Evans, A. Rhodes, W. Alhazzani, M. Antonelli, C. M. Coopersmith, C. French, F. R. Machado, L. McIntyre, M. Ostermann, H. C. Prescott, C. Schorr, S. Simpson, W. Joost Wiersinga, F. Alshamsi, D. C. Angus, Y. Arabi, L. Azevedo, R. Beale, G. Beilman, E. Belley-Cote, L. Burry, M. Cecconi, J. Centofanti, A. C. Yataco, J. De Waele, R. P. Dellinger, K. Doi, B. Du, E. Estenssoro, R. Ferrer, C. Gomersall, C. Hodgson, M. H. Møller, T. Iwashyna, S. Jacob, R. Kleinpell, M. Klompas, Y. Koh, A. Kumar, A. Kwizera, S. Lobo, H. Masur, S. McGloughlin, S. Mehta, Y. Mehta, M. Mer, M. Nunnally, S. Oczkowski, T. Osborn, E. Papathanassoglou, A. Perner, M. Puskarich, J. Roberts, W. Schweickert, M. Seckel, J. Sevransky, C. L. Sprung, T. Welte, J. Zimmerman and M. Levy	Original	https://www.ncbi.nlm.nih.gov/pubmed/34643578	https://journals.lww.com/ccmjournal/fulltext/2021/11000/executive_summary__surviving_sepsis_campaign_.14.aspx	No abstract available.
51.540	ERS/EAACI statement on adherence to international adult asthma guidelines	10.1183/16000617.0132-2021	AA	Thorax	TLRC	F. Herth	international	2021		A. G. Mathioudakis, O. Tsilochristou, I. M. Adcock, A. Bikov, L. Bjermer, E. Clini, B. Flood, F. Herth, I. Horvath, O. Kalayci, N. G. Papadopoulos, D. Ryan, S. Sanchez Garcia, J. Correia-de-Sousa, T. Tonia, H. Pinnock, I. Agache and C. Janson	Original	https://pubmed.ncbi.nlm.nih.gov/34526316/	https://publications.ersnet.org/content/errev/30/161/210132	Guidelines aim to standardise and optimise asthma diagnosis and management. Nevertheless, adherence to guidelines is suboptimal and may vary across different healthcare professional (HCP) groups.Further to these concerns, this European Respiratory Society (ERS)/European Academy of Allergy and Clinical Immunology (EAACI) statement aims to: 1) evaluate the understanding of and adherence to international asthma guidelines by HCPs of different specialties via an international online survey; and 2) assess strategies focused at improving implementation of guideline-recommended interventions, and compare process and clinical outcomes in patients managed by HCPs of different specialties via systematic reviews.The online survey identified discrepancies between HCPs of different specialties which may be due to poor dissemination or lack of knowledge of the guidelines but also a reflection of the adaptations made in different clinical settings, based on available resources. The systematic reviews demonstrated that multifaceted quality improvement initiatives addressing multiple challenges to guidelines adherence are most effective in improving guidelines adherence. Differences in outcomes between patients managed by generalists or specialists should be further evaluated.Guidelines need to consider the heterogeneity of real-life settings for asthma management and tailor their recommendations accordingly. Continuous, multifaceted quality improvement processes are required to optimise and maintain guidelines adherence. Validated referral pathways for uncontrolled asthma or uncertain diagnosis are needed.
51.539	Correction to: Key summary of German national treatment guidance for hospitalized COVID19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)	10.1007/s15010-021-01665-y	ALI	Ghd, KUM, MHH, UMR	ARCN, BREATH, CPC-M, UGMLC	T. Welte, K. F. Rabe	national	2021		J. J. Malin, C. D. Spinner, U. Janssens, T. Welte, S. Weber-Carstens, G. Schalte, P. Gastmeier, F. Langer, M. Wepler, M. Westhoff, M. Pfeifer, K. F. Rabe, F. Hoffmann, B. W. Bottiger, J. Weinmann-Menke, A. Kersten, P. Berlit, M. Krawczyk, W. Nehls, F. Fichtner, S. Laudi, M. Stegemann, N. Skoetz, M. Nothacker, G. Marx, C. Karagiannidis and S. Kluge	Other	https://www.ncbi.nlm.nih.gov/pubmed/34414563	https://link.springer.com/article/10.1007/s15010-021-01665-y	No abstract available.
51.538	[Treatment of COVID-19 with Inhaled Glucocorticoids - Statement of the German Respiratory Society (DGP), the Austrian Society of Pneumology (OGP) and the German Society of Allergology and Clinical Immunology (DGAKI)]	10.1055/a-1488-5373	AA, ALI	Ghd	ARCN	K. F. Rabe	international	2021		M. Idzko, M. Lommatzsch, C. Taube, E. Eber, B. Lamprecht, F. Horak, W. Pohl, K. F. Rabe, J. C. Virchow, E. Hamelmann, M. Pfeifer, T. Bauer and R. Buhl	Original	https://www.ncbi.nlm.nih.gov/pubmed/34000741	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1488-5373	No abstract available.
51.537	[Statement of the German Society for Pulmonology and Respiratory Medicine Regarding the Regulation to Use FFP and Surgical Masks in the General Population]	10.1055/a-1375-6717	General Lung and Other	UMR, KUM	UGMLC, CPC-M	D. Nowak	international	2021		D. Dellweg, P. M. Lepper, D. Nowak, T. Köhnlein, U. Olgemöller and M. Pfeifer	Original	https://pubmed.ncbi.nlm.nih.gov/33598902/	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1375-6717	On January 19, 2021, a new regulation on the mask requirement was issued in an initiative by the federal and state governments. This regulation obliges citizens to wear medical masks on public transport and in shops. In its statement, the German Society for Pneumology and Respiratory Medicine (DGP) describes the technical background of the various medical masks and explains their functionality using the associated standards. The DGP comes to the conclusion that FFP masks of the EN 149 standard were designed for the self-protection of the wearer and ensure this if the mask is worn properly and closes tightly to the face. Incorrect use must be avoided at all costs. Surgical masks in accordance with the EN 14683 standard were designed to protect against bacteria-carrying aerosols and, due to their design, have a rather low self-protection component. Community masks are not yet subject to any official standard. Community masks with electrostatic properties and high filtration performance could represent a reusable alternative in the future. Depending on the severity of their illness, patients with heart and/or lung diseases require a stress test with a mask to minimize medical risks.
51.536	[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]	10.1055/a-1321-3400	ALI, COPD	ASK, Ghd, MHH, Thorax, UKH, UMR	ARCN, BREATH, CPC-M, TLRC, UGMLC	K. F. Rabe, F. C. Ringshausen, C. F. Vogelmeier, N. Reinmuth, M. Reck, J. Gottlieb, T. Welte	national	2021		M. Lommatzsch, K. F. Rabe, C. Taube, M. Joest, M. Kreuter, H. Wirtz, T. G. Blum, M. Kolditz, H. Geerdes-Fenge, R. Otto-Knapp, B. Hacker, T. Schaberg, F. C. Ringshausen, C. F. Vogelmeier, N. Reinmuth, M. Reck, J. Gottlieb, S. Konstantinides, F. J. Meyer, H. Worth, W. Windisch, T. Welte and T. Bauer	Original	https://www.ncbi.nlm.nih.gov/pubmed/33242887	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1321-3400	No abstract available.
51.535	[Oxygen in the acute care of adults : Short version of the German S3 guideline]	10.1007/s00063-021-00884-3	General Lung and Other	MHH	BREATH	J. Gottlieb	national	2021		J. Gottlieb, P. Capetian, U. Hamsen, U. Janssens, C. Karagiannidis, S. Kluge, M. König, A. Markewitz, M. Nothacker, S. Roiter, S. Unverzagt, W. Veit, T. Volk, C. Witt, R. Wildenauer, H. Worth and T. Fühner	Review	https://www.ncbi.nlm.nih.gov/pubmed/34651197	https://link.springer.com/article/10.1007/s00063-021-00884-3	BACKGROUND: Oxygen is a drug with specific properties, a defined dose-effect range and side effects. In 2015, in a sample of UK hospital patients, 14% were treated with oxygen, of which only 42% had a prescription. Health care workers are often uncertain about the relevance of hypoxemia, and there is limited awareness of the risks of hyperoxemia. Numerous randomized controlled trials on oxygen therapy have recently been published. METHODS: As part of the guideline program of the Working Group of Scientific Medical Societies e. V. (AWMF), this S3 guideline was developed with the participation of 10 medical societies on the basis of a literature search up to 02/01/2021. The system of the Oxford Centre for Evidence-Based Medicine (CEBM) (The Oxford 2011 Levels of Evidence) was used to evaluate the literature. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE), and a formal consensus process of recommendations was performed. RESULTS: The guideline contains 34 evidence-based recommendations on the indication, prescription, monitoring, and discontinuation of oxygen therapy in acute care. The indication for oxygen is mainly hypoxemia. Hypoxemia and hyperoxemia should be avoided, since both increase mortality. The guideline recommends target ranges of oxygen saturation for acute oxygen therapy without differentiating between different diagnoses. Target areas depend on the risk for hypercapnia and ventilation status. The guideline provides an overview of available oxygen delivery systems and contains recommendations for their selection based on patient safety and comfort. CONCLUSION: This is the first German guideline on the use of oxygen in acute care. It is aimed at medical professionals who use oxygen in and outside hospitals and is valid until June 30th, 2024.
51.533	[German S3 Guideline - Oxygen Therapy in the Acute Care of Adult Patients]	10.1055/a-1554-2625	General Lung and Other	MHH	BREATH	J. Gottlieb	national	2021		J. Gottlieb, P. Capetian, U. Hamsen, U. Janssens, C. Karagiannidis, S. Kluge, M. Konig, A. Markewitz, M. Nothacker, S. Roiter, S. Unverzagt, W. Veit, T. Volk, C. Witt, R. Wildenauer, H. Worth and T. Fuhner	Original	https://www.ncbi.nlm.nih.gov/pubmed/34474487	https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1554-2625	BACKGROUND: Oxygen (O2) is a drug with specific biochemical and physiologic properties, a range of effective doses and may have side effects. In 2015, 14 % of over 55 000 hospital patients in the UK were using oxygen. 42 % of patients received this supplemental oxygen without a valid prescription. Healthcare professionals are frequently uncertain about the relevance of hypoxemia and have low awareness about the risks of hyperoxemia. Numerous randomized controlled trials about targets of oxygen therapy have been published in recent years. A national guideline is urgently needed. METHODS: A S3-guideline was developed and published within the Program for National Disease Management Guidelines (AWMF) with participation of 10 medical associations. Literature search was performed until Feb 1st 2021 to answer 10 key questions. The Oxford Centre for Evidence-Based Medicine (CEBM) System ("The Oxford 2011 Levels of Evidence") was used to classify types of studies in terms of validity. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used and for assessing the quality of evidence and for grading guideline recommendation and a formal consensus-building process was performed. RESULTS: The guideline includes 34 evidence-based recommendations about indications, prescription, monitoring and discontinuation of oxygen therapy in acute care. The main indication for O2 therapy is hypoxemia. In acute care both hypoxemia and hyperoxemia should be avoided. Hyperoxemia also seems to be associated with increased mortality, especially in patients with hypercapnia. The guideline provides recommended target oxygen saturation for acute medicine without differentiating between diagnoses. Target ranges for oxygen saturation are depending on ventilation status risk for hypercapnia. The guideline provides an overview of available oxygen delivery systems and includes recommendations for their selection based on patient safety and comfort. CONCLUSION: This is the first national guideline on the use of oxygen in acute care. It addresses healthcare professionals using oxygen in acute out-of-hospital and in-hospital settings. The guideline will be valid for 3 years until June 30, 2024.
51.534	[Guideline for the Diagnosis and Treatment of Asthma - Addendum 2020 - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]	10.1055/a-1352-0296	AA	KUM, UMR, Ghd	CPC-M, UGMLC, ARCN	R. Bals, D. Nowak, K. F. Rabe, C. Vogelmeier	international	2021		R. Buhl, R. Bals, X. Baur, D. Berdel, C. P. Criee, M. Gappa, A. Gillissen, T. Greulich, P. Haidl, E. Hamelmann, F. Horak, P. Kardos, K. Kenn, L. Klimek, S. Korn, H. Magnussen, D. Nowak, O. Pfaar, K. F. Rabe, J. Riedler, T. Ritz, K. Schultz, A. Schuster, T. Spindler, C. Taube, C. Vogelmeier, A. von Leupoldt, F. Wantke, J. Wildhaber, H. Worth, A. Zacharasiewicz, M. Lommatzsch, V. Unter Mitwirkung der folgenden Wissenschaftlichen Gesellschaften: Deutsche Gesellschaft fur Arbeitsmedizin und Umweltmedizin e, V. Deutsche Gesellschaft fur Rehabilitationswissenschaften e and V. Deutsche Gesellschaft fur Gynakologie und Geburtshilfe e	Original	https://www.ncbi.nlm.nih.gov/pubmed/33728628	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1352-0296	The present addendum of the guideline for the diagnosis and treatment of asthma (2017) complements new insights into the diagnosis and management of asthma as well as for the newly approved drugs for the treatment of asthma. Current, evidence-based recommendations on diagnostic and therapeutic approaches are presented for children and adolescents as well as for adults with asthma.
51.614	Joint Statement of the German Respiratory Society and German Society of Thoracic Surgery in Cooperation with the German Radiological Society: Structural Prerequisites of Centres for Interventional Treatment of Emphysema	10.1159/000511599	PLI	ASK, LMU, Thorax	CPC-M, TLRC	C. P. Heussel	national	2021		W. J. Gesierich, K. Darwiche, F. Dollinger, R. Eberhardt, S. Eisenmann, C. Grah, C. P. Heussel, R. H. Huebner, J. Ley-Zaporozhan, F. Stanzel, S. Welter and H. Hoffmann	Original	https://www.ncbi.nlm.nih.gov/pubmed/33412545	https://karger.com/res/article/100/1/52/285303/Joint-Statement-of-the-German-Respiratory-Society	Interventional treatment of emphysema offers a wide range of surgical and endoscopic options for patients with advanced disease. Multidisciplinary collaboration of pulmonology, thoracic surgery, and imaging disciplines in patient selection, therapy, and follow-up ensures treatment quality. The present joint statement describes the required structural and quality prerequisites of treatment centres. This is a translation of the German article "Positionspapier der Deutschen Gesellschaft fur Pneumologie und Beatmungsmedizin und der Deutschen Gesellschaft fur Thoraxchirurgie in Kooperation mit der Deutschen Rontgengesellschaft: Strukturvoraussetzungen von Zentren fur die interventionelle Emphysemtherapie" Pneumologie. 2020;74:17-23.
51.615	Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021)	10.1007/s15010-021-01645-2	ALI	Ghd, KUM, MHH	ARCN, BREATH, CPC-M	T. Welte, K. F. Rabe	national	2021		J. J. Malin, C. D. Spinner, U. Janssens, T. Welte, S. Weber-Carstens, G. Schalte, P. Gastmeier, F. Langer, M. Wepler, M. Westhoff, M. Pfeifer, K. F. Rabe, F. Hoffmann, B. W. Bottiger, J. Weinmann-Menke, A. Kersten, P. Berlit, M. Krawczyk, W. Nehls, F. Fichtner, S. Laudi, M. Stegemann, N. Skoetz, M. Nothacker, G. Marx, C. Karagiannidis and S. Kluge	Original	https://www.ncbi.nlm.nih.gov/pubmed/34228347	https://link.springer.com/article/10.1007/s15010-021-01645-2	PURPOSE: This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19. METHODS: The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation. RESULTS: The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D3 should not be used in COVID-19 routine care. CONCLUSION: For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
51.616	Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up	10.1016/j.annonc.2021.11.005	LC	Ghd	ARCN	M. Reck	international	2021		S. Popat, P. Baas, C. Faivre-Finn, N. Girard, A. G. Nicholson, A. K. Nowak, I. Opitz, A. Scherpereel and M. Reck	Original	https://pubmed.ncbi.nlm.nih.gov/34861373/	https://www.sciencedirect.com/science/article/pii/S0923753421048201?via%3Dihub	No abstract available.
51.617	Reorganisation of GP surgeries during the COVID-19 outbreak: analysis of guidelines from 15 countries	10.1186/s12875-021-01413-z	ALI, General Lung and Other	MHH	BREATH	H. Lingner	international	2021		R. Tsopra, P. Frappe, S. Streit, A. L. Neves, P. J. Honkoop, A. B. Espinosa-Gonzalez, B. Geroglu, T. Jahr, H. Lingner, K. Nessler, G. Pesolillo, O. S. Sivertsen, H. Thulesius, R. Zoitanu, A. Burgun and S. Kinouani	Original	https://www.ncbi.nlm.nih.gov/pubmed/34000985	https://bmcprimcare.biomedcentral.com/articles/10.1186/s12875-021-01413-z	BACKGROUND: General practitioners (GPs) play a key role in managing the COVID-19 outbreak. However, they may encounter difficulties adapting their practices to the pandemic. We provide here an analysis of guidelines for the reorganisation of GP surgeries during the beginning of the pandemic from 15 countries. METHODS: A network of GPs collaborated together in a three-step process: (i) identification of key recommendations of GP surgery reorganisation, according to WHO, CDC and health professional resources from health care facilities; (ii) collection of key recommendations included in the guidelines published in 15 countries; (iii) analysis, comparison and synthesis of the results. RESULTS: Recommendations for the reorganisation of GP surgeries of four types were identified: (i) reorganisation of GP consultations (cancelation of non-urgent consultations, follow-up via e-consultations), (ii) reorganisation of GP surgeries (area partitioning, visual alerts and signs, strict hygiene measures), (iii) reorganisation of medical examinations by GPs (equipment, hygiene, partial clinical examinations, patient education), (iv) reorganisation of GP staff (equipment, management, meetings, collaboration with the local community). CONCLUSIONS: We provide here an analysis of guidelines for the reorganisation of GP surgeries during the beginning of the COVID-19 outbreak from 15 countries. These guidelines focus principally on clinical care, with less attention paid to staff management, and the area of epidemiological surveillance and research is largely neglected. The differences of guidelines between countries and the difficulty to apply them in routine care, highlight the need of advanced research in primary care. Thereby, primary care would be able to provide recommendations adapted to the real-world settings and with stronger evidence, which is especially necessary during pandemics.
51.618	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis	10.1159/000512315	DPLD	ITEM, JLU, KUM, LMU, Thorax, UMR	BREATH, CPC-M, TLRC, UGMLC	J. Behr*, A. Gunther, L. Fink, D. Jonigk, P. Markart, A. Prasse, J. C. Schupp	national	2021		J. Behr, A. Gunther, F. Bonella, J. Dinkel, L. Fink, T. Geiser, K. Geissler, S. Glaser, S. Handzhiev, D. Jonigk, D. Koschel, M. Kreuter, G. Leuschner, P. Markart, A. Prasse, N. Schonfeld, J. C. Schupp, H. Sitter, J. Muller-Quernheim and U. Costabel	Original	https://www.ncbi.nlm.nih.gov/pubmed/33486500	https://karger.com/res/article/100/3/238/285298/S2K-Guideline-for-Diagnosis-of-Idiopathic	Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease. Diagnosis of IPF requires considerable expertise and experience. Since the publication of the international IPF guideline in the year 2011 and the update 2018 several studies and technical advances have occurred, which made a new assessment of the diagnostic process mandatory. The goal of this guideline is to foster early, confident, and effective diagnosis of IPF. The guideline focusses on the typical clinical context of an IPF patient and provides tools to exclude known causes of interstitial lung disease including standardized questionnaires, serologic testing, and cellular analysis of bronchoalveolar lavage. High-resolution computed tomography remains crucial in the diagnostic workup. If it is necessary to obtain specimens for histology, transbronchial lung cryobiopsy is the primary approach, while surgical lung biopsy is reserved for patients who are fit for it and in whom a bronchoscopic diagnosis did not provide the information needed. After all, IPF is a diagnosis of exclusion and multidisciplinary discussion remains the golden standard of diagnosis.
51.619	Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up()	10.1016/j.annonc.2021.03.207	LC, General Lung and Other	Ghd	ARCN	M. Reck	international	2021		A. C. Dingemans, M. Fruh, A. Ardizzoni, B. Besse, C. Faivre-Finn, L. E. Hendriks, S. Lantuejoul, S. Peters, N. Reguart, C. M. Rudin, D. De Ruysscher, P. E. Van Schil, J. Vansteenkiste, M. Reck and E. G. C. E. a. clinicalguidelines@esmo.org	Original	https://www.ncbi.nlm.nih.gov/pubmed/33864941	https://www.sciencedirect.com/science/article/pii/S0923753421011133?via%3Dihub	No abstract available.
51.620	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021	10.1097/ccm.0000000000005337	ALI	MHH	BREATH	T. Welte	international	2021		L. Evans, A. Rhodes, W. Alhazzani, M. Antonelli, C. M. Coopersmith, C. French, F. R. Machado, L. McIntyre, M. Ostermann, H. C. Prescott, C. Schorr, S. Simpson, W. J. Wiersinga, F. Alshamsi, D. C. Angus, Y. Arabi, L. Azevedo, R. Beale, G. Beilman, E. Belley-Cote, L. Burry, M. Cecconi, J. Centofanti, A. Coz Yataco, J. De Waele, R. P. Dellinger, K. Doi, B. Du, E. Estenssoro, R. Ferrer, C. Gomersall, C. Hodgson, M. Hylander Møller, T. Iwashyna, S. Jacob, R. Kleinpell, M. Klompas, Y. Koh, A. Kumar, A. Kwizera, S. Lobo, H. Masur, S. McGloughlin, S. Mehta, Y. Mehta, M. Mer, M. Nunnally, S. Oczkowski, T. Osborn, E. Papathanassoglou, A. Perner, M. Puskarich, J. Roberts, W. Schweickert, M. Seckel, J. Sevransky, C. L. Sprung, T. Welte, J. Zimmerman and M. Levy	Original	https://pubmed.ncbi.nlm.nih.gov/34605781/	https://journals.lww.com/ccmjournal/fulltext/2021/11000/surviving_sepsis_campaign__international.21.aspx	No abstract available.
51.621	Update of the S2k guideline on the management of IgE-mediated food allergies	10.5414/ALX02257E	AA	FZB	ARCN	U. Jappe	international	2021		M. Worm, I. Reese, B. Ballmer-Weber, K. Beyer, S. C. Bischoff, B. Bohle, K. Brockow, M. Classen, P. J. Fischer, E. Hamelmann, U. Jappe, J. Kleine-Tebbe, L. Klimek, B. Koletzko, L. Lange, S. Lau, U. Lepp, V. Mahler, K. Nemat, M. Raithel, J. Saloga, C. Schafer, S. Schnadt, J. Schreiber, Z. Szepfalusi, R. Treudler, M. Wagenmann, T. Werfel and T. Zuberbier	Original	https://www.ncbi.nlm.nih.gov/pubmed/34263109	https://www.dustri.com/article_response_page.html?artId=188232&doi=10.5414/ALX02257E&L=0	No abstract available.
51.622	Workplace-related inhalation test - Specific inhalation challenge: S2k Guideline of the German Society for Occupational and Environmental Medicine e.V. (DGAUM), the German Society for Pneumology and Respiratory Medicine e.V. (DGP) and the German Society for Allergology and Clinical Immunology e.V. (DGAKI)	10.5414/alx02280e	AA	KUM	CPC-M	D. Nowak	national	2021		A. M. Preisser, D. Koschel, R. Merget, D. Nowak, M. Raulf and J. Heidrich	Original	https://www.ncbi.nlm.nih.gov/pubmed/34646977	https://www.dustri.com/article_response_page.html?artId=188826&doi=10.5414/ALX02280E&L=0	No abstract available.
51.623	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	10.1183/13993003.00879-2022	PH	JLU, MHH	BREATH, UGMLC	M. M. Hoeper, H. A. Ghofrani, K. M. Olsson	international	2022		M. Humbert, G. Kovacs, M. M. Hoeper, R. Badagliacca, R. M. F. Berger, M. Brida, J. Carlsen, A. J. S. Coats, P. Escribano-Subias, P. Ferrari, D. S. Ferreira, H. A. Ghofrani, G. Giannakoulas, D. G. Kiely, E. Mayer, G. Meszaros, B. Nagavci, K. M. Olsson, J. Pepke-Zaba, J. K. Quint, G. Rådegran, G. Simonneau, O. Sitbon, T. Tonia, M. Toshner, J. L. Vachiery, A. Vonk Noordegraaf, M. Delcroix and S. Rosenkranz	Original	https://pubmed.ncbi.nlm.nih.gov/36028254/	https://publications.ersnet.org/content/erj/61/1/2200879	No abstract available.

Clinical Impact

DZL Engagements